Skip to main content
Erschienen in: Health and Quality of Life Outcomes 1/2022

Open Access 01.12.2022 | Review

Understanding lifestyle self-management regimens that improve the life quality of people living with multiple sclerosis: a systematic review and meta-analysis

verfasst von: Olivia C. Wills, Yasmine C. Probst

Erschienen in: Health and Quality of Life Outcomes | Ausgabe 1/2022

Abstract

Background

Lifestyle self-management as an intervention for people living with multiple sclerosis (plwMS) is an emerging area of research. Previous reviews have highlighted a need to systematically identify effective self-management regimens that influence the health and well-being of plwMS using a common metric of success.

Objectives

To examine the effectiveness of lifestyle self-management strategies and interventions aimed at improving the quality of life (QOL), and/or disability of plwMS. The review also aimed to narratively explore common elements of self-management interventions that were effective at improving the outcomes of interest.

Methods

A systematic search was performed using five scientific databases. The review process followed the Cochrane Handbook for Systematic Reviews of Interventions  and was registered with PROSPERO (Ref: CRD42021235982).

Results

A total of 57 studies including 5830 individuals diagnosed with MS, met the inclusion criteria. Self-management interventions included physical activity, fatigue, dietary, stress/coping, emotional, symptom and medical management, and lifestyle and wellbeing programs. Self-reported QOL improved in 35 of 47 studies. Dietary intervention had no statistically significant overall effect on reducing MS disability, (P = 0.18). Heterogeneity limited the ability to pool the effects from a large number of eligible studies of the same design.

Conclusion

Multicomponent self-management interventions, multimodal delivery methods, and cognitive behavioural theory principles were common elements of self-management interventions that improved the QOL of plwMS. However, these results should be interpreted with caution and care should be taken in its clinical application. This review has the potential to inform future management practices for plwMS and has revealed a significant gap in the literature, warranting high-quality, large-scale experimental, and observational studies that address lifestyle management.
Hinweise

Supplementary Information

The online version contains supplementary material available at https://​doi.​org/​10.​1186/​s12955-022-02046-1.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
MS
Multiple sclerosis
DMT
Disease-modifying therapy
plwMS
People living with MS
QOL
Quality of life
EDSS
Expanded disability status scale
PDDS
Patient-determined disease steps
RoB
Risk of bias
RCT
Randomised control trial
NOS
Newcastle–Ottawa scale
NHMRC
National health and medical research council

Introduction

Rationale

Living with multiple sclerosis (MS) is associated with unpredictable and debilitating neurological symptoms [1]. These symptoms include physical challenges (i.e. fatigue, pain, weakness, spasticity), cognitive deficits (i.e. memory loss, slow processing, poor concentration), and/or emotional symptoms (i.e. anxiety, mood swings, irritability, depression) that fluctuate throughout the disease course, regardless of the MS phenotype [1, 2]. While medical management, including the provision of disease-modifying therapies (DMT’s), is important to maintain good health when living with MS, the impact of these symptoms is not restricted to routine healthcare visits. For most people living with MS (plwMS), these symptoms are experienced daily and create a multitude of challenges that can significantly impact quality of life (QOL) [2, 3]. Therefore, it is the day-to-day management of the disease course and symptoms that can have a profound impact on the current and future health and well-being of plwMS.
Self-management is a relatively new phenomenon within healthcare but has received increased attention as an effective management strategy for chronic health conditions; it is the ideology that acknowledges neurological conditions, such as MS, as a continuous experience [4]. Self-management focuses on equipping the individual with the skills and ability to manage their symptoms, monitor medication regimens and physical disability, engage in physical activity, maintain nutritional status, and adjust to the psychological demands of their condition [5, 6]. There is considerable evidence that self-management interventions are effective in improving the health and functional status, knowledge, adherence to treatment, and the physical, psychological, and social domains of QOL among people with chronic conditions [79]. The emergence of lifestyle self-management as an intervention for plwMS is a growing area of focus, and while currently limited, the effectiveness of self-management interventions holds promise [10].
A systematic review conducted by Kidd et al. examined the impact of self-management interventions on the psychological well-being of plwMS [11]. Despite the inclusion criteria, the limited number of published studies specific to MS care at the time (n = 10) and the heterogeneity between the included studies made it difficult to compare the effectiveness of different treatment strategies on self-reported outcome measures. Similarly, a second review exploring self-management support in people with neurological conditions generally, also concluded that the limited number of studies (n = 39) and the diversity in reported self-management outcome measures challenged the ability to comment on the overall effectiveness of the strategies [12]. More recently, Yamaguchi et al. examined the potential of self-management for people living with HTLV-1 associated myelopathy by reviewing the literature within an MS context. Again, the included studies reported inconsistent outcome measures (i.e. QOL, self-efficacy, cognitive changes) and only a limited range of medical, role (i.e. social life and independence) and emotional management strategies [13].
Previous reviews [1113], therefore, highlight a need to systematically identify effective elements of self-management regimens that influence the health and well-being of plwMS using a common metric of success. QOL was chosen as an accepted outcome measure in clinical studies and has been identified as an important measure in MS research as it incorporates the personal and social context of a person’s life [14]. Moreover, Mitchell et al. recommended that studies of interventions in MS populations use assessments of QOL rather than impairment or disability measures alone [15].

Aims and objectives

Therefore, the present review aimed to examine the effectiveness of lifestyle self-management strategies and interventions aimed at improving QOL, as the primary outcome, and/or disability among plwMS [14, 15]. The review also aimed to narratively explore common elements of self-management interventions that were effective at improving the outcomes of interest.

Methods

Registration and protocol

The present review was guided by the Cochrane Handbook for Systematic Reviews of Interventions [16] and reported according to the Preferred Reporting Items for Systematic Reviews and Meta Analysis (PRISMA) 2020 statement [17] and 27-item PRISMA checklist [17]. The review protocol was registered with the International Prospective Register of Systematic Reviews (PROSPERO) [18] (Ref: CRD42021235982) in February 2021, to reduce the potential for bias through a transparent review process [19].

Eligibility criteria

Studies were included in the review if they met the following criteria:
Types of studies and publications Studies published in peer-reviewed journals, including both experimental and observational studies. Non-English studies were excluded. Studies including case studies, review articles, feasibility and pilot studies, protocols, grey literature, and publications including conference abstracts, editorials, and monographs were also excluded. No date restrictions were applied to the final search.
Types of participants Adults aged \(\ge 18\) years with a clinical diagnosis of MS using the McDonald criteria (2001, 2005, 2010, or 2017) [20] regardless of their time since diagnosis. Studies that included people diagnosed with a clinically isolated syndrome phenotype, pregnant or breastfeeding females, or paediatric MS were excluded.
Types of interventions A study that described a self-management intervention followed by a participant was included. A self-management intervention was defined as a strategy that provided the individual with the opportunity to learn self-management skills by focusing on the tasks and/or healthy behaviour(s) in a person’s life, supporting them to accomplish a task, and assist in the management of their condition. The MS Research Australia Modifiable Lifestyle Factors guidance documents were used to classify self-management interventions [21]. Therefore, elements of self-management included any combination of symptom management strategies, diet and nutrition, physical activity and exercise, stress management, fatigue management, meditation/relaxation therapy, psychological management, rehabilitation strategies, supplementation use, and sun exposure [21].
Types of comparators Any comparator was considered for inclusion, and studies with no control groups were also included. The control arms of the intervention studies included participants who did not receive treatment or received usual care.
Types of outcomes Studies that described QOL as a primary outcome, or disability as a primary or secondary outcome, using a validated measure were included. This included, but was not limited to, the 36-item Short Form Survey (SF-36), multiple sclerosis impact scale (MSIS-29), multiple sclerosis quality of life-54 (MSQOL-54), quality of life-3 (QOL-3), short form-12 (SF-12), short form-8 (SF-8), Euro-quality of life, Hamburg quality of life questionnaire MS (HAQUAMS), and the World Health Organization QOL instrument (WHOQOL) [22].
Measures of disability included the expanded disability status scale (EDSS) and patient-determined disease steps (PDDS). The EDSS is a clinically administered assessment scale, and plwMS are assigned a score that corresponds to their level of ambulatory ability (ranging from 0: normal neurological exam/no disability to 10: death due to MS) in 0.5 increments [23, 24]. The PDDS is a self-reported tool to identify the level of physical disability in plwMS, which strongly correlates with the EDSS [25]. The tool is scored on a scale from 0 (normal; functionally normal with no limitations on lifestyle) to 8 (bedridden). Additional measures of disability included lesion burden (number of new lesions, size of lesions) as measured by MRI, number of relapses in a certain time period (relapse rate), and Guy’s neurological disability scale [26].

Search strategy

The research question in the PICO format was: What is the effect of lifestyle self-management strategies and/or interventions on QOL and/or disability in plwMS? A systematic search was conducted using five scientific databases: Cochrane Library, CINAHL via EBSCOhost platform, MEDLINE via Ovid platform, PubMed via ProQuest platform, and Scopus via Elsevier. Although PubMed is a subset of MEDLINE, both MEDLINE and PubMed databases were searched to ensure that the most recent studies were identified [27]. A preliminary search was performed in February 2021 to determine the feasibility of the search by identifying sentinel articles. The final search was conducted on 8 April 2021 (OW).
The search strategy included alternative phrases, spelling, and truncations, using both controlled vocabulary and free-text terms. For a detailed search strategy, please refer to Additional file 1: data 1. To increase the sensitivity, manual hand searching of the reference lists of extracted systematic reviews and meta-analyses was performed to obtain additional relevant studies.

Selection process

A three-phase screening process was implemented to ensure that the included studies met eligibility criteria. All studies were exported to Covidence (Covidence Systematic Review Software, 2019, Veritas) to manage the screening process, and duplicates were removed. Two reviewers (OW and ES) independently screened titles and abstracts of the search results. Where consensus was not reached, a third and more senior researcher (YP) was consulted. For studies and reviews that met the inclusion criteria, the full text was retrieved and screened by two researchers (OW and YP). Discrepancies were resolved by discussions between the two researchers.

Data extraction

One author (OW) extracted relevant information from the included studies based on the Cochrane Consumers and Communication Review Group’s data extraction template [16]. Information extracted from each study included: study details (country, setting, date published), first author, study methodology (study design, recruitment, groups), participant characteristics (sex, age, MS phenotype, duration of disease, EDSS or PDDS score), study characteristics (intervention description, comparator/control description), description of primary and secondary outcomes (QOL or disability measurement tool used), results and a summary of the conclusions. Corresponding authors of studies with missing data were contacted via email to obtain additional information to be used in the synthesis of the results. No responses were obtained.
The effect measures of randomised control trials (RCT) included continuous outcome measures for both QOL and disability variables, which were summarised as the mean difference (\(\pm\) standard deviation) from pre to post intervention, unless otherwise stated. For observational study designs, the relative risk was reported where available from the included studies.

Data synthesis

The authors (OW, YP) identified what self-management regimen was being explored in each study and categorised it into one of five dimensions based on MS Australia’s Modifiable Lifestyle Factors Guidance document  [21]. This included: (1) physical activity, (2) diet, (3) fatigue management, (4) coping, depression, stress, and emotional management, and (5) symptom and medical management. Some interventions had multiple components (i.e. diet, exercise, and energy conservation); therefore, these interventions were categorised into a sixth dimension of (6) lifestyle and wellbeing programs. Individual studies were qualitatively synthesised under each self-management dimension to identify the findings related to participant outcomes. The outcomes are reported quantitatively in the final data summary table. The primary outcome measure was QOL (including their respective domains), and the secondary outcomes were measures of disability such as EDSS, relapse rate, and number and volume of T1 and/or T2 weighted brain lesions. Statistical significance was set at P < 0.05.
A meta-analysis was performed when there were two or more studies under the same self-management dimension that used the same disability measure or QOL domain with compatible summary measures (i.e. mean change (SD)), using Review Manager (RevMan) (Mac OS X, Version 5.4, The Cochrane Collaboration, 2020). Summary estimates were reported for studies of randomised controlled trials only, as the heterogeneity of comparing different study designs may increase the complexity of the analyses and impact the interrelation of quantitative outcomes [16, 28].
An inverse variance with random effects model was used because of the heterogeneity among participants in terms of MS disability and population characteristics [29]. The RevMan Calculator was used to calculate the standard deviation from the 95% confidence intervals and reported changes in means [30]. The I2 statistic was used to quantify the proportion of total variation attributable to between-study heterogeneity. Heterogeneity was categorised according to the Cochrane guidelines: (1) I2 = 0–40%: low heterogeneity; (2) I2 = 30–60%: moderate heterogeneity; (3) I2 = 50–90%, substantial heterogeneity; and (4) I2 = 75–100%: considerable heterogeneity [16].

Risk of bias assessment

The risk of bias (RoB) of each study was appraised according to the study design. Version 2 of the Cochrane RoB tool, as recommended in the Cochrane Handbook for Systematic Reviews of Interventions [16], was used to assess RoB in each RCT. The studies were appraised according to the RoB arising from (1) the randomisation process, (2) deviations from the intended interventions (effect of assignment to intervention), (3) missing outcome data, (4) measurements of the outcome, and (5) selection of the reported result. A proposed RoB judgment for each domain was generated using an algorithm [31] and each study was assessed as having low risk, some concerns, or high RoB.
The RoB in non-randomised studies of interventions was assessed using the ROBINS-I tool [32]. This tool focuses on seven domains of bias including: bias due to confounding, selection of participants into the study, classification of interventions, deviations from intended interventions, missing data, outcome measurements and selection of the reported results. Risk levels of low, moderate, serious, critical, or insufficient information were assigned to each of these domains.
The RoB in case–control and cohort studies was assessed according to the Newcastle Ottawa Quality Assessment Scale (NOS) [33]. This scale was adapted from the NOS for cohort studies to provide RoB assessment of cross-sectional studies [34]. A star system was used to appraise each study under the following domains: (1) the selection of study groups, (2) the comparability of the study groups, and (3) ability to identify the exposure or outcome of interest. Each study was awarded one star for each criterion under the selection and exposure/outcome categories, and a maximum of two stars for the comparability category. Therefore, cohort/case–control studies with 7–8, 5–6, 4 and 0–3 stars were identified as very good, good, satisfactory, or unsatisfactory, respectively. Cross-sectional studies with 5, 4, 3 or 0–2 stars were identified as very good, good, satisfactory, and unsatisfactory, respectively [35].

Certainty assessment

The certainty of the body of evidence of the quantitative synthesis was assessed using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) criteria [36]. The certainty of the body of evidence considered within-study risk of bias, precision and consistency of effect estimates, directness of evidence and risk of publication bias. An overall GRADE was determined as one of four levels of evidence: high, moderate, low and very low, by the two researchers (OW, YP). Randomised controlled trials begin with a high level of evidence. Factors that may increase or decrease the quality level of a body of evidence have been described elsewhere [36].

Results

Study selection

A total of 1664 references were identified from the database search, and an additional 14 references were obtained from manual searches. After removing the duplicates (n = 762), 902 references were retained. The full texts of 310 references were screened, and 43 studies met the inclusion criteria. Therefore, 57 studies were included in this systematic review [3793]. the full selection process is presented in Fig. 1.

Study characteristics

The included studies were published between 1996 and 2021, with 70% of studies published after 2010 and 33% of studies published after 2016. The highest proportion (35%) of included studies were conducted in the USA (n = 20) [40, 41, 4749, 5153, 59, 60, 63, 74, 81, 8386, 88, 91, 93] followed by 28% in Europe (n = 16; Belgium, Italy, Netherlands, Slovenia, Denmark, Germany, Turkey, Finland, Norway and Switzerland) [39, 42, 43, 45, 46, 50, 55, 61, 62, 6466, 68, 71, 73, 77], 16% in Asia (n = 9; Iran and India) [55, 57, 58, 69, 70, 72, 75, 82, 92] and 9% in both Australia (n = 5) [55, 56, 7880] and UK (n = 5) [38, 67, 76, 89, 90]. In total, 70% (n = 40) of included studies were of experimental study designs of which 85% (n = 34) were RCT's [38, 4346, 50, 51, 5356, 59, 6063, 6676, 83, 84, 86, 8891]. The remaining 30% of studies were of an observational study design including case–control (n = 8) [40, 41, 52, 65, 71, 81, 92, 93], cohort (n = 7) [37, 39, 64, 7880, 87] and cross sectional analysis (n = 2) [47, 48] studies. The duration of the studies ranged from one week to five years. The full data summary is presented in Table 1.
Table 1
Results of included studies (n = 57) examining lifestyle management on QOL and disability, characterised according to self-management dimension
Author, year (country)
Study design
Study duration
Sample size (attrition)
Population characteristics, EDSS
RRMS
PPMS
SPMS
Mean disease duration, yrs
Intervention
Control
Self-management dimension
Outcomes (Measure)
Results
Key findings
Beatus et al. [37](USA)  
Observational study
1 week 
N = 41 
Female 34,
Male 7,
Age 45 (8.54) 
EDSS unknown.
   
14.8 (8.38)
One-week summer retreat to encourage physical activity, art and social interaction.  
NA      
Physical activity      
QOL (MSQOL-54)
No significant change between pre and post test on the physical component of QOL (P=0.214).A significance difference when comparing pre and post test measures on the mental portion of QOL (P=0.035).
Retreat had no positive effects on physical QOL, however did increase the mental perception of QOL in subjects with MS. 
Carter et al. [38] (UK)               
RCT
12 months
N = 120 (83%) 
InterventionFemale 43, Male 17,
Age 46 (8.4)
EDSS 3.8 (1.5) Control:Female 43,
Male 17,
Age 45.7 (9.1)EDSS 3.8 (1.5)
N = 98
N = 4
N = 18
Intervention: 9.2 (7.9) Control: 8.4 (7.4)
12- week EXMES + usual care including: aerobic, strength, resistance training incorporating self directed exercise at home. 
Usual care only 
Physical activity 
QOL (MSQOL-54) Disability (EDSS)
Difference in mean QOL change at 3, 9 months respectively:Intervention:Physical health component 59.7 (20.6)*, 54.1 (21.7)Mental health component65.5 (20.2)*, 65.9 (21.0)ControlPhysical health component 52.5 (21.4), 53.3 (21.1)Mental health component60.8 (20.0), 63.8 (24.1)*Significant change, P<0.05.There were no significant change in EDSS between in the intervention or control in 3 or 9 months post treatment (P>0.05).
Intervention could be an effective way to implement rehabilitation into a health care setting.
D'Hooghe et al. [39](Belgium) 
Observational cohort study
10 months
N = 9 (100%)
Female 6, Male 3,
Age 42 (23-40)a EDSS 3 (1-4)a
üN = 9 
  
9 (3-24)a
5 day expedition to Machu Picchu (45.5km walk).(Fitness training 5 months prior + Follow up for 4 months post expedition).
NA
Physical activity
Walking ability (ESES)
ESES increased by 1 (36 – 37) within 8 months (P>0.05).The relapse rate during the study period did not differ from the relapse rate in the year prior.
Fluctuations were observed in self- reported disease steps
Fasczewski et al. [40](USA) 
Mixed methods 
 
N = 15 
Female 11,
Male 1
Age 43.5 (± 10.03)  
üN = 15
  
7 ± (± 4.34)
Qualitative interviews lasting 20- 60 mins were used to explore physical activity motivation and benefits. The transcribed interviews were coded into clusters of meaning.
NA
Physical activity
QOL(QOL survey)
QOL measures:
Emotional: 19.56 (± 3.24)
Physical: 20.34 (± 3.52)Two main themes emerged of how PA and QOL relate: (1) Physical fitness/strength (2) QOL/mental wellness/happiness.
Motivation to participate in long term PA reportedly increases QOL. 
Fasczewski et al. [41](US) 
Mixed methods 
6 month 
N = 16 
Female 14,
Male 2,
Age 55.1 (± 9.93)
PDDS 2.9 (± 1.79) 
N = 12
N = 2
N = 1
14.7 (± 11.72)
7x 90min medical therapeutic yoga sessions + education + relaxation therapy. A follow up structured interview used to assess retention of physical activity behaviours.
None 
Physical activity (Medical therapeutic yoga therapy) 
QOL(QOL-3) Disability (PDDS)
Only emotional QOL (P= 0.019) significantly improved between pre- and post-test measures.
Greatest motivator for exercise was an improvement in QOL and functioning.
Intervention only increased emotional QOL.
Feys et al. [42](Belgium) 
Uncontrolled interventional
10 months
N = 57 (74%) 
Group 1:
Female 22,
Male 2,
Age 37 (± 10)
PDDS 0.9 (± 0.3) Group 2:
Female 11
Male 7, Age 50 (± 11) PDDS 3.2 (± 1.3)
N = 33
N = 4
N = 5
Group 1:7 (± 7) 
Group 2:12 (± 8)
Single education day followed by 3x 45 min practical sessions of different sports.Subgroups of disability level (Authors hypothesised that effects on education on physical activity could be greater in persons that have little physical restrictions).
NA
Physical activity 
QOL(SF-36) 
Group 1 change at 6 months for:Physical QOL: 0.21(6)Mental QOL: 0.6(7.7) Group 2 change at 6 months for:
Physical QOL: -0.24(± 7)
Mental QOL: -0.7(± 9.1) 
No significant change in QOL domains; Physical health (P=0.29) and Mental health (P=0.75) were found between groups or over time.
No significant difference was found between groups. 
Flachenecker et al. [43](Germany)  
RCT
6 months 
N = 84 (76%) 
InterventionFemale 22,
Male 9,
Age 47.6 (± 9.2)
EDSS 4.3 (IQR 1.5)b Control:Female 17,
Male 13,
Age 46.4 (± 12.2)
EDSS 4 (IQR 3)b
N = 39
  
Intervention: 13.4 (± 7.9) 
Control: 9 (± 7.5)
Goal-oriented, multimodal inpatient rehabilitation program after discharge that promoted exercise.  
Usual care
Physical activity
QOL (MSIS-29)
Improvements in HRQOL in intervention were sustained for up to 6 months (p < 0.001), whereas HRQOL in the control group returned to baseline scores at 3 months.Similar results for physical and psychological subscales of the MSIS-29.
With the reduction of fatigue, HRQoL increased.
Khan et al. [44](Australia) 
RCT 
12 month 
N = 101 (98%) 
InterventionFemale 40,
Male,
21
Age 49.7 (± 8.96)
EDSS 0-3: 8, 3.5-6: 36, 6.5+: 17 
Control: Female 32,
Male 8,
Age 51.2 (± 9.51)
EDSS 0-3: 11, 3.5-6: 23, 6.5+: 6
N = 31
N = 14
N = 56
Intervention: 10.52 (± 6.61) 
Control: 9.7(± 8.11)
Acute neurological and intensive MD rehabilitation (5 days x 3h therapy sessions a week). Intervention offered education, health promotion, bladder retraining and mobilisation. 
Waitlist 
Physical activity (Exercise) 
QOL
(GHQ-28)
Mean difference between intervention and control for GHQ subscales:
Anxiety: -0.055 (CI: -1.85 – 1.74)
Depression: 0.212 (CI: -1.32 to 1.74)
Somatic: -1.25 (CI: -3.3 to 0.79)
Social: -0.68 (CI: -2.91 to 0.83) 
No significant effect of intervention on QOL. Therefore further exploration is required. 
Kjolhede et al. [45](Denmark) 
RCT 
6 months 
N = 35 (83%) 
Age 43 (± 8)
EDSS 2.9 (2-4)a 
N = 35
  
7 (± 7)
Progressive resistance training for 24 weeks, completed twice a week. Sessions consisted of four lower and two upper body exercises. 
Habitual lifestyle.  Followed interventiona after 24 weeks.
Physical activity (Resistance training) 
Disability (EDSS, MRI)
Non- significant decrease in EDSS from baseline to T48 (P=0.75).
All participants had a mean increase of 0.40 (CI: 0.001 - 0.558) in the number of lesions from T0 to T48 (p<0.01). No interaction was observed for T2 lesion volume.
Possible restorative effect of resistance training on brain structures, but the interpretation should be cautious. 
Langeskov- Christensen et al. [46](Denmark)   
RCT 
6 months
N = 86 (73%) 
InterventionFemale 26,
Male 17,
Age 44 (± 9.5),
EDSS 2.7 (± 1.4)
Control:Female 26,
Male 17,
Age 45.6 (± 9.3)
EDSS 2.8 (± 1.6)
N= 75
N= 6 
N= 5
Intervention: 10.9 (± 7.9)
Control: 8.6 (± 6.0)
Twice weekly-supervised physical aerobic exercise followed by self guided physical activity.    
Habitual lifestyle followed by supervised physical aerobic exericse.  
Physical activity (aerobic exercise)        
QOL (MSIS-29) Disability(T2 lesion count & load, relapse rate)    
Between- group change after 24 weeks:
Physical QOL: -1.6 (-6.6 to 3.5)
Mental QOL: -3.4 (-9. to 2.9)
T2 lesion count: 0.92 (-1.09 to 2.93)
T2 lesion load: -0.16 (-0.73 to 0.40) 
Relapse rate:
Intervention; 0 (0.0-0.07)
*Control; 0.45 (0.28-0.61)*Significantly different
Intervention failed to affect QOL 
Motl et al. [47] (USA) 
Prospective cross sectional
 
N = 196 
Female 173,
Male 23,
Age 46.1 (± 9.8)
N = 174
N = 3
N = 19
9 (± 7.1)
Pedometer and accelerometer during waking hours for 7 days + A battery of questionnaires on the 8th day.
NA
Physical activity 
QOL(SWLS)
The direct path between physical activity and QOL was non significant (.
Those with MS who were more physically active had greater self-efficacy and better functional capacity, which, in turn, was associated with greater QOL.
Motl et al. [48](USA)  
Cross sectional
6 months
N = 292 (95%)
Female 245,
Male 47,
Age 48 years (10.3) 
EDSS Unknown
N = 246
N = 12
N = 34
10.3 (± 7.9)
Accelerometer during waking hours for 7 days & repeated at 6 months.
No accelerometer
Physical activity
QOL: (LMSQOL)Disability: (PDDS)
Association between physical activity and QOL (P= 0.73). Indicators of physical activity and QOL (LMSQOL λ = 0.84) were statistically significant. Those who were more physically active reported higher QOL.
Indirect relationship between changes in physical activity and QoL over time, based on fatigue, pain, social support and self-efficacy.
Motl et al. [49] (US)  
Panel study 
6 months 
N = 269 (98%) 
Female 233,
Male 46,
Age 45.9 (9.6)
PDSS 2 (0-6)a 
N = 233
  
8.8 (± 7)
Association between changes in physical activity and walking impairment. Frequency and intensity of participants exercise levels were recorded.
NA
Physical activity
Disability (PDDS)
Mean change:PDDS: -0.1 (1.0)
Insignificant Significant path coefficients between baseline physical activity and walking impairment (P=0.0001) and between follow-up physical activity and walking impairment (P=0.01).
Results support change in physical activity as a determinant of walking impairments over time.
Mutluay et al. [50](Turkey) 
RCT 
6 weeks 
N = 40 
InterventionFemale 8,
Male 12,
Age 40.3 (± 6)
EDSS 4.85 (± 1.3) 
Control:
Female 8,
Male 12,
Age 38.1 (± 7)
EDSS 4.18 (± 1.7)
N = 12
N = 8
N = 20
Intervention: 9.8 (± 5.6) 
Control: 9 (± 4.6)
Home training programme, monitored by the physiotherapist by recalls to hospital for checking compliance with the assigned exercise schedule.
No exercises assigned.
Physical activity (breathing enhanced upper extremity exercise)
Disability (EDDS)
Mean change:Intervention: -0.23 (± 0.44)Control: 0.08 (± 0.37)Not significant (P > 0.05).  
Intervention had no effect on EDSS.
Petjan et al. [51](Utah)  
RCT 
15 weeks 
N = 54 (85%) 
InterventionFemale 15,
Male 6,
Age 41.1 (± 2)
EDSS 3.8 (± 0.3) 
Control:Female 16,
Male 9,
Age 39 (± 1.7)
EDSS 2.9 (± 0.3)
   
Intervention: 9.3 (± 1.6) 
Control: 6.2 (± 1.1)
15-week aerobic training program to improve measures of physical fitness.
No exercise
Physical activity
Disability (EDSS)
Mean change:Intervention: EDSS 3.8 (± 0.3) to 3.7 (± 0.3) Control:EDSS 2.9 (± 0.3) to 2.8 (± 0.3)Insignificant change P < 0.05  
Intervention had no effect on EDSS. 
Pilutti et al. [52](USA) 
RCT
6 months 
N = 82 (92%) 
Intervention:Female 30,
Male 11,
Age 48.4 (IQR 9.1)bPDDS 2 (IQR 4)b 
Control:Female 32,
Male 9,
Age 49.5 (IQR 9.2)bPDDS 3 (IQR 3) b
N = 65
N = 7
N = 10
Intervention: 10.6 (IQR 7.1)b 
Control: 13.0 (IQR 9.1)b
Behavioural intervention that focused on increasing lifestyle physical activity through coaching sessions + a battery of questionnaires at the 6 month period. 
Did not receive intervention
Physical activity 
QOL(MSIS-29) 
Disability (PDDS)
No significant difference between groups on the physical and psychological QOL domains post intervention (P = 0.06 & P = 0.11 respectively).
Mean difference between pre- post intervention not reported.  
Lifestyle physical activity might be effective in supervised exercise training for improving HRQOL in MS patients. 
Oken et al. [53](Portland)  
RCT 
6 months 
N = 69 (83%) 
Exercise:Female 13,
Male 2,
Age 48.8 (± 10.4)
EDSS 2.9(± 1.7) 
Yoga:Female 20
Male 2,
Age 49.8 (± 7.4)
EDSS 3.2 (± 1.7) 
Control:Female 20
Male 0,
Age 48.4 (± 9.8)
EDSS 3.1(± 2.1)
    
90 min yoga classes once per week. With emphasis on breathing for concentration and relaxationORAerobic exercise + stretching
Waitlist
Physical activity (Yoga)
QOL (SF-36)
Mean change:Exercise:Physical QOL: 76.7 (± 25.8) to 61.7 (± 41.0)
Emotional QOL: 82.2 (± 27.8) to 88.9 (± 30) 
Yoga:Physical QOL: 50 (44) to 48.8 (39.1)Emotional QOL: 72.4 (± 24) to 64.9 (± 17.9) 
Waitlist:Physical QOL: 40.3 (± 37.5) to 52.8 (± 43.6)
Emotional QOL: 72.2 (± 43.2) to 72.2 (± 36.6)
Yoga intervention only improved the energy and Fatigue (Vitality) dimensions.
Sangelaji et al. [54](Iran)  
RCT
14 months 
N = 61 (90%) 
Intervention:Female 24,
Male 15,
Age 33.05 (± 7.68)
Control:Female 15,
Male 7 Age 32.05 (± 6.35) 
    
10 weeks (3x 60-90 min sessions per week) of combined exercise classes.
Avoided plannedphysical or rehabilitation activity for 10 weeks. 
Physical activity (exercise therapy) 
QOL specific for MS Disability (EDSS)
Mean change at time 1:Mental QOL 16.36 (*Physical QOL 12.17 (*EDSS -0.13 ( Time 2:
Mental QOL 2.82 (Physical QOL -1.27 (EDSS -0.15 ( Time 3:Mental QOL 13.54 (*Physical QOL 10.90(*EDSS -0.28 (*P<0.05.
Rehabilitation can be important in keeping MS patients capable of doing their daily activities. 
Savsek et al. [55](Slovenia)  
Exploratory RCT 
12 weeks 
N = 28
Intervention:Female 11,
Male 3,
Age 39.7 (± 6.7)
EDSS 2.5 (1.0-6.5)a
Control:Female 12,
Male 2,
Age 42.3 (± 5.7)
EDSS 3 (1.0-6.0)a
N=28
  
Intervention: 8.4 (± 6.1) 
Control: 14.8 (± 4.5)
60min aerobic exercise twice weekly.
Participants followed prescribed exercise intensity and exercise. All participants were taking Fingolimod. 
Normal daily routine
Physical activity (Aerobic exercise) 
QOL (MSQOL-54) 
Disability (MRI- T2 lesion, EDSS) 
Mean difference between groups at 3 month follow up:
EDSS: -0.31 (-0.84 to 0.22)
Physical health composite QOL: -2.38 (-10.74 to 5.98)
Mental health composite QOL: 1.47 (-8.13 to 11.07).
Intervention was strongly associated with a decrease in lesion count: (T2 lesion count change: -0.13 (-1.90 to 1.64)).
Positive effect of intervention on the preservation of several regional brain volumes, possibly indicating a slowing of the neurodegenerative process in pwMS 
Sutherland et al. [56] (Australia)  
RCT (
10 weeks 
N = 22 
InterventionFemale 6,
Male 5,
Age 47.18 (± 4.75) 
Control:Female 6
Male 5
Age 45.45 (± 5.05)
   
Intervention: 7 (± 5.59) 
Control: 6.18 (± 3.63)
Water and land aerobics 3x 45min weekly for 10 weeks.
No special activity
Aerobic exercise
QOL (MSQOL-54)
Mean change:Intervention:Physical: 15.2 (± 4.6) to 17.1 (± 4.4)
Emotional: 19.6 (± 4.2) to 22.4 (± 4.1)
Control:Physical: 15.4 (± 4.0) to 15.9 (± 4.0)
Emotional: 20.7 (5.1) to 20.8 (6.7) 8 out of 11 subscales of QOL, showed a significant improvement (P<0.05)
Aerobic exercise can alter HRQOL for people with MS.
Vasudevan et al. [57] (India)  
Single group pre/ post experimental 
4 months 
N = 10 
Female 7,
Male 3,
Age range 31- 52
    
12 private customized yoga sessions and three group sessions, conducted by yoga therapists.
 
Physical activity (Yoga)
QOL (MSQOL-54)
QOL domain: bPhysical composite: 72.1 (IQR 57 - 80) – 78.9 (69 - 81)
Mental composite: 73 (65 - 85) to 85.3 (84 - 88)
Overall: 73.4 (64 – 83) to 79.2 (70 – 87)Not significant (P>0.05).
Yoga may be encouraged in addition to medical management for better QOL, which includes social and cognitive function.
Abolghasemi et al. [58](Tehran city)  
Experimental pre test/ post test with control 
 
N = 32 
InterventionFemale 7,
Male 9,
Age 31.75 ((8.25) Control:Female 9
Male 7,
Age 32.5 (90.58)
    
12x 75 min supportive-expressive therapy sessions. At the twelfth session, subjects were asked to answer questionnaire’s on quality of life again.
Followed the medicaltreatments
Coping, depression, stress and emotional management
QOL (WHOQOL-B)
Mean QOL pretest VS posttest:Intervention: 35.47 (6.76) VS 54.06 (7.05)
*Control: 40.65 (14.66) VS 42.29 (12.48)**Significant difference between pre and post-intervention scores in both groups (P<0.01). The effect of supportive-expressive therapy on enhancing quality of life was 0.418.
Intervention is effective for enhancing the QOL MS patients.
Besharatet al. [59] (US)  
RCT
3 months
N = 24
InterventionFemale 12,
Male 0,
Age 35 (7.45)
EDSS 2.3 
Control:Female 12,
Male 0,
Age 30 (± 4.1)
EDSS 2.7
   
Intervention: 2.8 
Control: 3.25
Mindfulness based stress reduction program. Training sessions involved mindfulness awareness during yoga/ stressful situations/ social interactions, body scan meditation.
Standard medical care for MS
Coping, depression, stress and emotional management (Stress management)
QOL(SF- 36)Disability (EDSS)
Mean QOL:Intervention -3.1 (± 4.74)*Control 2.51 (± 2.28)*Significant increment in quality of life.
Training in mindfulness may offer MS patients a self-management of symptoms that enhances QOL.
Ehde et al. [60](USA)    
RCT 
12 months 
N = 163 
InterventionFemale 67,
Male 8,
Age 51 (± 10.1)
EDSS <4: 194.5 – 6.5: 46>7: 10
Control:
Female 75,
Male 13,
Age 53.2 (± 10)
EDSS <4: 234.5 – 6.5: 55>7: 10
N = 91
N = 72
 
Intervention:<5: 215-9: 1710-19: 29>20: 8 
Control:<5: 215-9: 2510-19: 26>20:16
Individual telephone delivered self management intervention including evidenced based cognitive behavioural and positive psychology strategies
Education in MS care
Coping, depression, stress and emotional management
QOL (SF-8)  
Physical HRQOL significantly improved (CI:-5.51 to -1.45) post treatment, favouring the self management intervention.This was maintained 6 months post intervention (-5.1o to -0.75, however not 12 months post. P<0.05.Mental HRQOL significantly improved post treatment, at 6 and 12 months in both intervention and control (P<0.05).
Validates telephone as a simple but effective method for improving aspects of QOL in the short term.
Grossman et al. [61](Switzerland)  
RCT
8 months
N = 150
InterventionFemale 59,
Male 19,
Age 45.93 (± 10)
EDSS 3.03 (± 1.12) 
Control:Female 60,
Male 14,
Age 48.68 (± 10.58)
EDSS 2.98 (± 0.83)
N = 123
 
N = 27
Intervention: 7.74 (± 0.9) 
Control: 9.71 (± 0.88)
Mindfulness based intervention (8-week 2.5h class program), based on: perception, acceptance of health changes, sense of control.
Regular medical care
Coping, depression, stress and emotional management (Mindfulness)
QOL (HAQUAMS)
Mean change QOL:InterventionPre/ post intervention: 0.18 (0.09 to 0.27)*6 month f/ u: 0.13 (0.00 to 0.25)* 
Control:Pre/ post intervention: -0.09 (-0.20 to 0.01)6 month f/ u: -0.05 (-0.16 to 0.07) *Significant difference in HAQUAMS QOL, P<0.05.
MBI may improve HRQOL for at least 8 months among mild to moderately severely impaired patients with MS.
Graziano 2014 [62] (Italy)   
RCT 
6 months 
N = 82 (66%) 
InterventionFemale 27,
Male 14,
Age 42.3 (8.5) 
Control:Female 24,
Male 17, Age 38.3 (10.1) 
EDSS Unknown
N= 77
N= 2
N= 3
Intervention: 8.6 (5.2) Control: 7.2 (5.3)
Four group based cognitive behavioural therapy sessions (2hr) over two months + a 6-month follow up + home relaxation tasks and self-practice of exercise. 
Informative sessions about stem cells, CAM and nourishment.
Coping, depression, stress and emotional management (Depression) 
QOL(MSQOL-54)  
QOLIntervention VS controlPretreatment: 13.39 (4.39) VS 12.43 (4.54)Posttreatment: 14.24 (3.62) VS 13.71 (4.00)6- months post: 14.96 (4.28)* VS  11.95 (5.40)*  
*Mean difference between groups at 6-month follow-up was significant (P = 0.034).
QOL increased over time in the intervention and decreased in control, which was found to be significant (P = 0.042). 
Hart et al. [63](USA)  
RCT 
16 weeks 
N = 60 (82.2%) 
Female 44,
Male 16,
Age 44.8 (± 10.3)
N = 60 
  
8.3 (3 months – 31.2 years)c
Individual, weekly cognitive behavioural therapyOR Supportive expressive group psychotherapyOR
Sertraline (medication).
Coping, depression, stress and emotional management
QOL (MSQOL-54) 
Disability(T25FW)
Mean QOL pre and post treatment:Physical 45.3 (15.6) VS 52.8 (16.0)*Mental 39.7 (14.9) VS 60.0 (21.1)**Significant improvements over time in the physical health composite scale, P<0.001.Change in depression scores significantly predicted post-treatment scores for the MSQOL total score, physical health composite scale, and the mental health composite scale (P<0.001).
Treatment for depression was related to better QOL in MS patients.
Jongen et al. [64](Netherlands)  
Observational cohort study 
6 months 
N = 94 (47 PwMS + support partners (93%) 
RRMS group 1:Female 16,
Male 4,
Age 42.7 (± 10.1)
EDSS 3.1 (± 1.2) 
PPMS group 1:Female 19,
Male 5,
Age 48.7 (± 7.6)
EDSS 5.5 (± 1.4)
N = 20
N = 2
N = 22
Group 1:8.4 (6.9) Group 2:17.5 (8.6)
Social Cognitive Can Do Program (SCDP) with participants and partners involved group sessions, consultations, theatre evening and joint activities.
NA
Coping, depression, stress and emotional management (stress management) 
QOL (MSQOL-54) 
Disability (EDSS)
Mean (SEM) % QOL change:RRMS group 1:Physical 1 month: 6.0% (5)Physical 3 months: 6.3% (5.9)Physical 6 months: 12.7% (4.8)* 
Mental 1 month: 21.4% (8.8)*Mental 3 months: 22.3% (10.7)*Mental 6 months: 22.3% (8.7)* 
PPMS group 2:Physical 1 month: 5.3% (8.2)Physical 3 months: 8.4% (10.7)Physical 6 months: 7.8% (8.0)
PPMS group 2: Mental 1 month: 11.5% (5.4)Mental 3 months: 5.5% (5.4)Mental 6 months: 3.2% (7.9) 
*Significant result, P<0.05.
6 months post SCDP; PwMS with a RR course or low disability may experience an improved mental and physical HRQoL. 
Jongen et al. [65](Netherlands)   
Exploratory, uncontrolled 
12 months 
N = 60 (66.7%) 
Female 25,
Male 13
EDSS unknown
N = 22
N = 14
  
As above.
NA 
Coping, depression, stress and emotional management (stress management)
QOL (MSQOL-54) 
Twelve months post treatment, physical QOL improved by almost 15%, reaching significance (P=0.032). Mental QOL increased by 17%, however this change was not significant (P=0.087).
12 months post treatment, persons with RRMS showed improved physical HRQoL.
Jongen et al. [66](Netherlands)   
RCT
3.5 years 
N = 158 (76%) 
InterventionFemale 69,
Male 10,
Age 40 (± 8.7)
EDSS 2.3 (± 1.03) Control:
Female 70,
Male 9,
Age 40 (± 9.4)
EDSS 2.3 (.13)
N = 158
  
Intervention: 6.5 (± 5.6) 
Control: 6.5 (± 5.3)
As above.
Any care or treatments that were deemed necessary by caregivers. 
Coping, depression, stress and emotional management (stress management) 
QOL (MSQOL-54) 
Mean QOL change:Intervention VS controlPhysical baseline: 53.2 (13.6) VS 54.7 (15.3)Physical 1 month: 55.3 (15.1) VS 64.1 (14.6)*Physical 3 months: 56.4 (14.3) VS 60.7 (17.1)Physical 6 months: 58.1 (14.0) VS 59.2 (17.2) 
Mental baseline: 63.4 (20.1) VS  60.9 (17.6)Mental 1 month: 64.1 (19.2) VS 69.1 (15.7)*Mental 3 months: 66.2 (20.2) VS  67.0 (16.2)Mental 6 months: 67.3 (18.2) VS 65.9 (17.8) 
*Significant result, P<0.05.
Intervention favoured CDT group at one month. 
Lincoln et al. [67](UK)   
RCT 
8 months 
N = 151 (85%) 
InterventionFemale , Male,
Age 44.5 (± 11.1) Control:Female ,
Male,Age 47.5 (± 10.5)
N = 103
N = 15
N = 30
Intervention: 9.2 (7.8) Control: 10.5 (8.0)
6x 2h group treatment sessions over 12 weeks. Sessionscovered topics including problem-solving,realistic goal setting and mental health and were taught strategies to reduce distress.
Received all otherrehabilitation routinely provided.
Coping, depression, stress and emotional management (stress management)
QOL(MSIS-29) Disability (Guy’s Neurological Disability Scale)
QOL difference (95% CI)Physical 4 months: 0.14 (12.3 to 0.8)*Physical 8 months: 0.20 (15.1 to 4.4.)* Psychological 4 months: 0.12 (11.8 to -0.6)
Psychological 8 months: 0.20 (15.1 to 4.4)*Significant difference, P<0.05. 
There was a significant difference between intervention and control for psychological QOL (P=0.037), but not for physical QOL (p-0.149).
Significant difference in psychological impact of MS QOL.
Aivo et al. [68](Finland)  
RCT           
12 month 
N = 30 (90%) 
InterventionFemale 9,
Male 6,
Age 37 (25-53)a
EDSS 2 (0-3.5)a 
Control:
Female 9,
Male 6,
Age 32 (22-47)aEDSS 2 (0-4)a
   
Intervention: 3 (0.6-15.2)a 
Control: 1.5 (0.3-4.7)a
20mg of cholecalciferol / 20000 IU of vitamin D3 , administered as one capsule once a week
Placebo
Diet (Vitamin D supplementation)
Disability (EDSS, MRI)
Mean difference in EDSS pre/ post intervention:Intervention: -0.3 (0.6)Control: -0.1 (0.7)No significant change (P=0.27). Number of T1 lesions decreased in both groups (control; P = 0.018,  vitamin D-treated group;P = 0.027).
Number of new or enlarging T2 weighted lesions was greater in the placebo group (P = 0.132).
Intervention reduced T1 enhancing lesions and lesion volume growth.
Ashtari et al. [69](Iran)  
RCT 
3 months 
N = 94 
InterventionFemale 37,
Male 10,
Age 31.4 (± 7.6)
EDSS 1.7 (± 0.6) Control:Female 41,
Male 6,
Age 34.6 (± 10.1)
EDSS 2 (± 0.9)
N = 94 
  
Intervention: 4.1(± 3.73) Control: 4.4 (± 3.9)
50,000 IU vitamin D3 every five days for 3 months+ Interferon-β (IFN-β) as main treatment.
Placebo + Interferon-β (IFN-β)
Diet (Vitamin D supplementation)
QOL (MSQOL-54) Disability (EDSS)
Mean difference in QOL components after 3 months:Intervention:Physical: 71.74 (Mental: 62.41 (*ControlPhysical: 69.55 (Mental: 60.99 (* *Significant difference after adjustment for age, sex, disease duration, and EDSS.
A positive change in mental QOL was reported by patients in intervention.  
Bitarafanet al. [70](Iran)  
RCT 
12 month 
N = 101 (92%) 
InterventionFemale 35,
Male 12,
Age 30.4 (6.9)
EDSS 1.3 (± 0.97) 
Control:Female 34,
Male 12,
Age 32.3 (± 5.9)
EDSS 1.4 (± 1.05)
N = 101 
  
Intervention: 4.3 
Control: 5.3
25000IU Vit. A for six months followed by 10000IU/d Vit. A for another six months.
Placebo
Diet (Vitamin A supplementation)
Disability (Relapse rate, MRI brain scan)
Mean difference in EDSS pre/post intervention:Intervention: 0.07 (0.23)Control: 0.08 (0.23) No significant difference between groups for relapse rate, number of enhanced lesions, volume of T2 hyper intensive lesions, new T2 lesions (P>0.05).
Vitamin A supplementation does not affect disease activity, but may inhibit disease progression in MS patients.
Kampan et al.[71](Norway)  
RCT 
96 weeks 
N = 71 (96%) 
InterventionFemale 24,
Male 11,
Age 40 (21-50)c
EDSS 2.5 (0-4.5)c 
Control:
Female 24,
Male 9,
Age 41 (26-50)a
EDSS 2 (0-4.5)a
N=68
  
Intervention: 11 (1-27)c 
Control: 10 (2-26)c
20,000IU vitamin D3 + 500 mg elemental calcium daily.
Placebo + calcium tablet
Diet (Vitamin D supplementation)
Disability (EDSS, ARR)
Mean difference in EDSS pre/ post intervention:Intervention: 0.16 (0.73)Control: 0.15 (0.71)No significant change (P=0.97).No significant change in ARR between groups after the intervention period (P=0.25). 
ARR was not reduced and EDSS was unchanged in intervention group. 
Kouchaki, E. et al. [72](Iran)   
RCT
12 weeks
N = 60 (100%) 
InterventionFemale 25,
Male 5,
Age 33.8 (8.9)
EDSS 2 (0-4.5)a 
Control:
Female 25,
Male 5,
Age 34.4 (9.2)
EDSS 2.5 (0-4)a
N = 60 
  
Intervention: 4.3 (2.8) 
Control: 4.3 (2.9)
Probiotic capsule containing Lactoba- cillus acidophilus, Lactobacillus casei, Bifidobacterium bifidum and Lactobacillus fermentum.
Placebo
Diet (Probiotic supplementation)
QOL(GHQ-28) Disability (EDSS, relapse rate)
Mean difference in EDSS pre/ post intervention:Intervention: -0.3 (0.6)Control: 0.1 (0.3)Probiotic intake significantly improved EDSS (P= 0.003) and GHQ-28 scores (P=0.002).
Probiotic intake had favourable effects on EDSS.
Torkildsen et al. [73](Norway)   
RCT
24 months
N = 92 (99%)
InterventionFemale 30,
Male 16,
Age 38.8 (± 8.4)
EDSS 1.94 (± 0.78) 
Control:
Female 29,
Male 16,
Age 38.3 (± 8.4)
EDSS 1.86 (± 0.86)
üN = 92
  
Intervention: 5.4  (5.4) 
Control: 5.8 years (5.9)
Oral omega- 3 fatty acid supplementcontaining EPA & DHA + 4iu/ gram tocopherol were added for antioxidative protection.After 6 months, all participants (intervention + control) received 44 μg of interferon beta-1a (Rebif ) 3 times per week for another 18 months.
Placebo 
Diet (Omega- 3 supplementation)
Disability (MRI brain scans, relapse rate, EDSS)
No significant effect of intervention on number of new T1 weighted Gd enhanced lesions, at 6, 9 or 24 months (P = .09, P=0.10, P=0.17, respectively).No significant difference between the treatment groups regarding new T1-weighted hypointense lesions after 24 months of treatment (P = 0.40).No difference in EDSS scores between the treatment groups after 24 months (P=0.63).
No beneficial effects of omega-3 fatty acid supplementation on disease activity in MS.
Weinstock-Guttman et al. [74](NY)   
RCT 
12 months 
N = 31 (87%) 
InterventionFemale 12,
Male 2,
Age 45.1 (± 7.7)
EDSS 1.9 (± 0.6) Control:Female 11,
Male 2,
Age 39.9 (± 10)
EDSS 2 (± 1.3)
N = 31
  
Intervention: 6.9 (5.9) 
Control: 4.6 (3.5)
6x fish oil capsules per day containing 1 g FO (65% o-3; EPA 1.98 g and DHA 1.32 g/day)+ Very low fat diet intake, (<15%).+ 400 units of Vit. E+ 1x multivitamin tablet+ 500mg calcium per day.
Olive Oil group+ Low cholesterol diet (<30% TF)+ Vit E, multivitamin+ 500mg calcium supplement. 
Diet(Fish oil supplementation + low fat diet)
QOL(SF-36) 
Disability (EDSS, relapse rate)
Significant change in physical composite scale (P=0.05) observed between intervention and control at 6 months.Worsening in EDSS scoers in the olive oil group (+0.0.35 EDSS points)Decrease in EDSS in the fish oil group (-0.07 EDSS points).Significant decrease in relapse rate when compared to 1 year prior to the study in both groups (P= 0.021, P=0.044).
Low fat diets have potential to improve the physical and emotional disease burden.Low fat diet + fish oil was more efficient at doing so. 
Zandi- Esfahan, S. et al. [75](Iran)  
RCT 
12 months 
N = 50 (82%) 
InterventionFemale 13,
Male 12,
Age 35.19 (± 9.97) 
Control:
Female 16,
Male 9,
Age 31.4 (8.41)
N = 50
   
Fingolimod + Fish oil (180 mg (EPA), 120 mg (DHA), and excipient (glycerin, purified water, tocopherol, sunflower oil, and tita- nium dioxide)
Fingolimod + Placebo - capsules
Diet(Fish oil supplementation)
Disability (EDSS)
Mean difference in EDSS pre/ post intervention:Intervention: 0.786 (1.04)Control: 0.875 (0.67)Changes between two groups showed no significant difference (P= 0.747).
Fish oil had no role in improving patients’ disability progression. Decreased EDSS can be attributed to taking Fingolimod. 
Ennis et al. [76](UK)  
Single blinded RCT (II) 
8 weeks
N = 62(32 intervention, 30 control) (98%) 
InterventionFemale 20,
Male 11,
Age 45(± 9)
Control:
Female 19,
Male 11,
Age 46 (± 8) 
N = 28
N = 11
N = 20
Intervention:7 (5) 
Control: 8 (6)
OPTIMISE program (3h weekly sessions) to provide people with the knowledge, skill and confidence to undertake health promoting activities.
Present level of care 
Lifestyle & wellbeing  (Exercise and physical activity, fatigue management, stress management, diet) 
QOL(SF-36)
Mean change in SF-36 domains pre/ post intervention:Intervention:Role Physical: 23.29 (± 53.98) (Role Emotional: 15.0 (± 88.91) (Control:Role Physical: -3.33 (± 36.98) (Role Emotional: 8.87 (± 40.07) 
Physical domain, mental health and general health domain were statistically significant in the intervention compared to the control group P=0.03, P<0.01, P<0.01 respectively.
Increase in health promotion has a significant effect on QOL. 
Feicke et al. [77](Germany)  
Prospective quasi- experimental evaluation study 
6 months 
N = 81 (73%) 
Intervention: Female 27,
Male 4,
Age 41.94 (± 11.7)
Control:
Female 23,
Male 10,
Age 37.12  (± 7.83) 
EDSS unknown
N = 32
N = 2
N = 2
Intervention: 0.97 (1.11) 
Control: 1.64 (1.45)
S.MS program which involved physical and emotional management strategies and support. 
Received brochurewhich covered the same content as the training program. 
Lifestyle & wellbeing  (Disease management, support strategies, coping strategies)
QOL (HAQUAMS)        
Mean changes in HAQUAMS from pre intervention to six month follow up:Intervention: 1.86 (± 0.55) to 1.84 (0.56)Control: 1.80 (± 0.52) to 2.00 (± 0.67) 
MS specific QOL decreased in control group and increased in the intervention from post intervention to 6 months follow up. 
Compared to the control group, ‘‘S.MS’’ participation was associated with a significant, sustained improvement of self-management and disease-specific quality of life. 
Hadgkiss et al. [78](Australia)   
Longitudinal cohortstudy 
5 year follow up
N = 387 attended retreat over 8 years (71%) 
Female 227
Male 47,
Age Unknown 
EDSS Unknown
    
Five day live in educational programme to assess the impact of modifiable lifestyle factors on MS outcomes.
NA
Lifestyle & wellbeing  (Diet, exercise, stress management) 
QOL (MSQOL-54)
One year follow changes were significant in:(P<0.001): role limitations- physical, emotional well- being, energy, health perceptions, cognitive function, health distress, overall QOL, change in health, physical and mental health composite), role limitations- emotional,(P=0.002): pain(P=0.001): social function
Five year follow up changes were significant in:(P<0.001): Role limitations- physical, role limitations- emotional, emotional well- being, energy, health perceptions, health distress, overall QOL(P=0.004): Physical and mental health composite,(P=0.043), social function cognitive function(P=0.009): Change in health
Overall QOL improved by 11.3% (p<0.001).Overall improvement in quality of life of 19.5% (p<0.001). 
Li, et al. [79](Australia)   
Longitudinal cohortstudy 
2.5 year follow up
N = 188 (58%) 
Female 94,
Male 15,
Age Unknown 
EDSS Unknown 
    
As above
NA
Lifestyle & wellbeing  (Diet, exercise, stress management) 
QOL (MSQOL-54)
One year follow changes were significant in:(P<0.001): role limitations- physical, health distress, overall QOL and mental health composite score. P=0.001: emotional wellbeing, energy, physical health composite score. P=0.019: health perceptions, P=0.04: cognitive function, P=0.012: sexual function, P=0.008: role limitations- emotional, P=0.002: pain, P=0.001: social function 
At 2.5 year follow up changes were significant in:P=0.015: emotional wellbeingP=0.044: energy,P=0.013: health perceptions,P=0.001: health distress,P=0.035: sexual function,P=0.031: Overall QOL,P=0.014: physical health composite, P=0.008: mental health composite
A significant improvement in short- and medium-term HRQOL for people with MS, 1 and 2.5 years after intervention.   
Marck et al. [80](Australia)  
Observational study 
3 years 
N=95 (82%) 
Female 69,
Male 26,
Age 44 (± 10.5)EDSS unknown 
N = 68
N = 9
N = 18 (Benign/ other)
49.5% = <2yr19%= 2-5yr17.9%=6-10yr13.7%= >11
5 day group workshop delivered by health care professionals to develop self- management skills. 
NA
Lifestyle & wellbeing (Diet, exercise, stress management) 
QOL (MSQOL-54)
Mean (95% CI) change:Mental health QOL:1 year: 9.2 (5.8 to 12.6)*3 years: 8.0 (4.2 to 11.8)* 
Physical health QOL:1 year: 8.0 (5.2 to 10.8)*3 years: 8.7 (5.3 to 12.2)* 
Significant improvement P<0.05.
QOL maintained up to 3 years post intervention.
Ng et al. [81](Canada)  
 
6 months 
N = 129  (64%)
Female 99,
Male 30,
Age 49 (11)
EDSS 3.5 (-9.5)a 
   
4 (± 2)
Interdisciplinaryeducational wellness program, consisting of physical and psychological evaluations, lectures and workshops.
NA
Lifestyle & wellbeing  (Symptom management, diet, exercise and physical activity, emotional management, goal setting, stress management, energy conservation)
QOL(SF-36)
Significant improvements in:Physical function at 1 month (p < 0.01) and 3 months (p = 0.04).Role physical subscale at 6 months (p = 0.02).Mental Health at 1 (p = 0.004) and 6 months (p = 0.01).No change after program participation in the remaining SF-36 categories; bodily pain, social function or role emotional (P>0.05).
Short-term wellness-program can result in significant positive changes in QOL for plwMS. These changes are stable up to at least 6 months.
Sahebalzamani et al. [82](Iran)  
Quasi experimental 
3 months 
N = 53 (94%) 
    
1-5 years: 25>5 years: 25
3- month self- care training program involving 6 x 50minute training sessions.
NA
Lifestyle & wellbeing (Symptom management, emotional management) 
QOL (MSQOL-54)
Mean difference pre VS post intervention:Physical health: 12.86 (± 2.39) VS 12.9 (± 2.39)*Mental health: 10.06 (± 1.88) VS 10.08 (1.88)* 
*Significant improvement (P<0.05)
+ * For pain, fatigue, perceived health, overall health, marital satisfaction, psychological health, feeling of wellbeing.
Self-care training to be effective on physical, emotional and psychological domains of quality of life in patients with MS. 
Stuifbergen et al. [83](USA)  
RCT
8 months
N = 121 (93%)
Female 113
Male 0,
Age 45.97 (± 10.09)
EDSSUnknown
N=62
  
10.76 (± 6.62)
8- week life style program (8x 90 min sessions)+ Bimonthly telephone calls for up to 3 months post program.
No intervention
Lifestyle & wellbeing (physical activity, diet, stress management, women's health) 
QOL(SF-36)
Mean QOL domain at baseline VS T4:Intervention:Role- physical: 42.9 (40.7) VS 46.9 (43.8)Role- emotional: 63.1 (40.5) VS 76.2 (36.0)Control:Role- physical: 38.2 (38.1) VS 41.4 (42.0)Role- emotional: 67.8 (42.2) VS 65.5 (42.5)
Bodily pain and mental health (P<0.05) were higher for the intervention group.Physical function, role- emotional, role-physical, bodily pain, social functioning, general health, mental health, vitality was significant (P<0.01).Stability in scores achieved by month 2
Intervention improved QOL domains: pain & mental health.
Finlayson et al. [84](USA)  
RCT
6 months 
N = 181 (80%) 
Female 143,
Male 38,
Age 56 (9)PDDS 4 (2) 
N=95
N=16
N=39
15 (± 9)
6 -week, group based intervention. 70 min teleconference calls facilitated by an OT. 
Waitlist
Fatigue management
QOL(SF-36) Disability (PDDS)
Mean (95% CI) difference between intervention and control pre/post intervention in QOL domains:Vitality: 6.99 (4.29 to 9.69)*Role emotion: 10.08 (4.13 to 16.04)*Mental health: 5.78 (3.89 to 7.67)*Social function: 7.95 (4.09, 11.82)*Role physical: 11.12 (6.22 to 16.02)*Physical function: 2.62 (0.52 to 4.71)*Significant difference P<0.05/8
Intervention was more effective than control for reducing fatigue impact and improving role- physical domain of QOL. 
Mathiowetz et al. [85](USA)  
Repeated measures clinical trial 
19 weeks 
N = 54 
Female 36,
Male 18,
Age 50 (31-74)c 
N = 20
  
9.5 (1-34)c
6x 2h weekly sessions incorporating lectures, discussions, long- and short-term goal setting, activity stations, and homework activities to teach energy conservation principles.
6 weeks symptom management course followed by 6 week intervention course.
Fatigue management (energy conservation)
QOL(SF- 36)
Mean difference week 1 VS week 19:Role physical: 26.9 (29) VS 26.9 (34)*Role emotional: 49.4 (41) VS 60.9 (42)Vitality: 34.1 (18) VS 43.3 (20)*Social: 59.1 (24) VS 67.5 (22)*Mental health: 65.9 (17) VS 71.2 (16)**Significant improvement post intervention, P<0.001.
Intervention is effective in improving some aspects of QOL for individuals with MS.
Mathiowetz et al. [86](USA)  
RCT
6 weeks 
N = 169(77%) 
Female 140,
Male 29,
Age 48.34 (8.44)  
N = 104
N = 10
N = 32
9.47 (± 7.44) 
Energy conservation course. 2h classes that covered rest, communication techniques, body mechanics and prioritisation.
6 week delayed intervention. 
Fatigue management 
QOL(SF-36)
Mean (95% CI) difference between intervention and control in QOL domains:Role- Physical: 15.18 (0.78 to 29.57)*Role- emotional: 13.23 (-6.77 to 33.24)Vitality: 11.64 (5.48 to 17.79)*Mental health: 6.12 (0.01 to 12.24)** Significant improvement, P<0.05.
Intervention increased some aspects of quality of life (vitality, mental health, physical health). 
Mulligan et al. [87] (NZ)  
Observational cohort study 
3 months
N = 23 (88%) 
Female 23,
Male 0,
Age 48.96 (± 8.13) 
EDSS unknown
N = 14
N = 2
N = 3
11.52 (± 9.95)
Minimise fatigue, maximise life program: 6 weeks, 2hr sessions/ wk.
NA
Fatigue management
QOL(SF-12)
Themes:(1) Achieving behaviour change to manage fatigue(2) Whole life effects
Minimise fatigue, maximise life positively affected lives of participants.
Plow et al. [88](Ohio)    
RCT 
6 months 
N = 208 (78.4%) 
Female 176,
Male 32,
Age 52.1 (± 8.4) 
PDDS:Mild: 34
Moderate: 41
Gait: 62
Early cane: 45
Late cane: 26
N = 176 
N = 6
N = 11
12.7 (± 8.6)
3 teleconference sessions+ 4 individually tailored phone calls + Fatigue course for energy conservation. 
(1) PA only(2) CC Health information 
Fatigue management  
QOL(MSIS)
Mean (95% CI) difference post test:PA- only VS CC:Physical function: -6.03 (-12.90 to 0.85)Mental function: -3.27 (-10.18 to 3.63)FM VS CC:Physical function: -5.60 (-12.18 to 0.99)Mental function: -3.40 (-9.96 to 3.17)FM VS PA- only:Physical function: 0.43 (-6.26 to 7.12)Mental function: -0.12 (-6.82 to 6.58)
Intervention had no effect on improving QOL.Future studies can experiment with number of teleconference sessions.
Thomas et al. [89](UK)  
RCT 
18 months 
N = 164 (89%) 
InterventionFemale 61,
Male 23,
Age 48 (10.2) 
Control:
Female 58,
Male 22,
Age 50.1(± 9.1)
N = 75
N = 13
N = 39
<1 year: 6, 1-5 years: 53,6-10 years: 32,11-15 years: 33, >16 years: 34
6x 90min sessions of the FACETS intervention plus current practice to assist 
Current local practice alone
Fatigue management
QOL(MSIS-29 V.1, SF-36)
Mean (95% CI) difference between intervention and control:MSIS-29: 1 year: 1.44 (-2.36 to 5.24)2 years: -1.56 (-6.45 to 3.34)No significant differences between the intervention and control for the MSIS-29 at follow up 1: P=0.46 OR follow up 2: P=0.53.
It may take longer for the intervention to impact on QOL. Therefore longer term follow up may be required.
Thomas et al. [90](UK)  
RCT 
1 year 
N = 164 (80%) 
InterventionFemale 61,
Male 23,
Age 48 (± 10.2)
PDDS <3: 184-5: 376>: 26 
Control:Female 58,
Male 22,
Age 50.1 (± 9.1)
PDDS <3: 154-5: 426>: 21
N = 75
N = 13
N = 39
Intervention:<1: 61-5: 536-10: 3211-15: 33>16: 34  
FACETS programme (6x 90 min sessions, weekly) for fatigue managmenet.
Received current local practice.
Fatigue management
QOL(MSIS-29, SF-36) 
Mean (95% CI) difference between intervention and control:Physical:1 year: 1.39 (-2.87 to 5.65)2 years: -0.81 (-5.91 to 4.28)3 years: -4.74 (-9.4 to -0.08)* Vitality:1 year: 4.42 (-1.22 to 10.06)2 years: 6.38 (0.45 to 12.32)*3 years: 6.64 (0.84 to 12.44)*
Improvements in QOL at 3 years f/u for physical QOL and vitality. 
Miller et al. [91](Ohio) 
RCT
12 months
N = 206 (81%) 
InterventionFemale 88,
Male 16
Age 48.1 (9.7) 
Control:Female 73,
Male 29,
Age 48.1 (9.1)
    
Access to a secure electronic messaging system between clinicians and plwMS.
Usual care
Symptom and medical management (symptom)
QOL(Euro- Quality of Life)
Mean difference between intervention and control at end of study:EQ-QOL: 76.3 (± 2.6)**Significant difference, P=0.04.No other between-group differences were found.
Access to messaging system did not lead to the expected improvements in patient outcomes.
Seifi et al. [92](Iran)  
Longitudinal cohortstudy 
 
N = 28 
Female 18,
Male 10,
Mean age 38 (24 - 55)c 
    
2x 45 min self- care sessions for controlling symptoms.
None
Symptom and medical management (Continence management, diet, exercise, energy preservation)
QOL (WHOQOL)
Mean difference (standard error) before and after self- care program:Physical health: -15.02 (2.72)*Psychological: 23.36 (2.42)*Social: -13.54 (2.78)*Living: -8.37 (1.70)**Significant difference (P < 0.001).
Self-care program leads to improved QOL. 
Stockl et al. [93](USA)   
Observational cohort study 
7 months 
N = 468 
InterventionFemale 131,
Male 25,
Age 53.3 (± 10.2)
Specialty pharmacy:Female 133,
Male 23,
Age 53.5 (± 10.1)
Retail pharmacy:Female 127,
Male 29,
Age 52.9 (± 10.5)
N = 195      
  
11.7 (± 8.8)      
DMT program (combined disease self management and medication therapy management) to improve knowledge and maximise therapeutic outcomes. 
(1) Retail pharmacyOR(2) speciality pharmacy 
Symptom and disease management (Medication) 
QOL(SF-12) Disability(MS relapse) 
Mean QOL domains at baseline VS 6 months:Physical: 37.7 (± 10.1) VS 37.9 (± 10.0)Mental: 48.4 (± 10.4) VS 49.9 (11.1)No significant change, (P>0.05). Relapse: 14% VS 9.3%** Significant change, P=0.03. 
DTM program decreased MS relapse rate, but there were no significant changes in QOL.
All data are reported as the mean (±SD) unless otherwise stated. aMean (range), bMedian (IQR), cMedian (range).Expanded disability status scale (EDSS), patient-determined disease steps (PDDS), multiple sclerosis quality of life (LMSQOL), satisfaction with life scale (SWLS), exercise self-efficacy scale (ESES), short form-36 (SF-36), multiple sclerosis impact scale- 29(MSIS-29), quality of life-3 (QOL-3), multiple sclerosis quality of life-54 (MSQOL-54), general health questionnaire-28 (GHQ-28), short form-8 (SF-8), World Health Organization Quality of Life (WHOQOL-B), timed 25 foot walk (T25FW), Hamburg quality of life questionnaire multiple sclerosis (HAQUAMS), annual relapse rate (ARR), multiple sclerosis impact scale (MSIS), short form-12 (SF-12)

Participant characteristics

The 57 included studies included a total of 5830 individuals diagnosed with MS, with a median of 82 individuals per study (IQR, 110). The majority (95%) of the studies included both female and male participants, with approximately 75% of the participants being female. Five percent of the studies (n = 3) were restricted to females [59, 83, 87]. Twenty-one percent (n = 12) included only participants with the RRMS phenotype [39, 45, 49, 55, 63, 6975] and 47% (n = 27) included participants with all MS phenotypes. The median age of the participants was 45 years (IQR 9.67), with the majority of studies having mean ages of participants in the 30-or 40-year age group. Of the 14 studies (25%) that included a EDSS score to quantify disability [38, 45, 50, 51, 54, 55, 59, 64, 68, 69, 71, 7375], the median score was 2.9 (IQR 1.8), suggesting most individuals had a relatively limited disability due to MS. The median disease duration of participants was 8.6 years since MS diagnosis (IQR 4.16).

Description of outcomes

QOL was most commonly measured at follow-up or post intervention using the MS Quality of Life-54 form (MSQOL-54) in 15 of the 57 studies (26%) [37, 38, 5557, 6266, 69, 7880, 82]. The Short Form-36 was used in a further 12 studies (21%) [42, 53, 59, 74, 76, 81, 83, 84, 86, 8890]. The most commonly used tool to measure neurologic disability was the EDSS in 14 out of 57 studies (25%) [38, 45, 50, 51, 53, 59, 64, 68, 69, 71, 72, 7476]. This was followed by the relapse rate (n = 7) [46, 7073, 74, 93], MRI brain scans, including lesion count and volume (n = 6) [45, 46, 55, 68, 70, 73] and the PDDS (n = 4) [41, 49, 52, 84].

Qualitative synthesis of individual studies

The most commonly reported intervention dimensions were physical activity and exercise (n = 21, 37%) [3757]; coping, depression, stress, and emotional management (n = 10, 18%) [5867]; diet (n = 8, 14%) [6875], lifestyle and wellbeing (n = 8, 14%) [7683]; fatigue management (n = 7, 12%) [8490] and symptom and medical management (n = 3, 5%) [9193]. Key findings are explored below for each dimension.

Physical activity interventions

Of the 21 studies that assessed physical activity, seven reported a significant improvement in QOL domains and only one saw a significant improvement in disability measures among plwMS [3757]. One study was delivered via multimodal means [43] and the remaining 20 were delivered face-to-face [3742, 4457]. The most common QOL domains that saw significant improvement among the seven studies were physical (n = 4), mental (n = 4), emotional (n = 2), energy (n = 1), and fatigue (n = 1) domains.
Disability was most commonly measured using EDSS (n = 6) and lesion characteristics (n = 3). The most common intervention activity was general exercise (n = 5), followed by aerobic exercise (n = 5) and yoga (n = 3). Other types include walking, expedition, live-in training programs, resistance training, and inpatient rehabilitation programs.
Among those studies reporting a significant improvement in outcome measures, group-based interventions were a common occurrence, and exercise sessions ranged from to 60–90 minutes in duration.
General exercise interventions ranged from six weeks to 14 months, with typical programs involving team sports, walking, and group activities. Of these, none of the general exercise programs saw a significant change in MS disability, with only one study reporting a significant improvement in QOL for up to 14-months after a combined exercise program.
Of the five studies assessing aerobic exercise [38, 46, 51, 55, 56], four reported significant improvements in QOL subscales [38, 51, 55, 56] including mental, physical, pain, energy, social, sexual function, fatigue, and overall QOL. Two studies reported a significant decrease in the disability measures [46, 55]. One of these studies was restricted to participants with only the RRMS phenotype and included only those prescribed fingolimod as a DMT. Among those studies exploring yoga as an intervention, two reported significant improvements in emotional, energy, and vitality QOL domains at the six month time point.

Coping, depression, stress and emotional management interventions

Of the ten studies that explored coping, depression, stress, and emotional self-management strategies [5867], seven studies were RCT's, all of which reported a significant improvement in QOL post intervention, relative to the controls [5963, 66, 67]. Controls were not exposed to the interventions and continued with routine standardised MS care. Six were delivered face to face [59, 6163, 66, 67] and one was delivered via telephone [60]. One of these studies was conducted among adults with a RRMS phenotype only, all others did not restrict the MS phenotype in their inclusion criteria. Physical (n = 6) and mental health (n = 5)-related QOL were the most common domains reported. A key finding was that significant improvements in QOL domains among the seven interventional studies were reported almost immediately and lasted for up to six months. Few studies have included data on the long-term effects of these interventions (i.e. 12 months and beyond).
Common theories, models, and practical strategies were used in the seven studies that reported a significant improvement in QOL domains. The most popular theory was cognitive behavioural theory (n = 3), followed by supportive/positive expressive psychotherapy (n = 3), and mindfulness practice (n = 2). Two studies explored the effect of the Social Cognitive Can Do Program (SCDP) among people with a RRMS phenotype [64, 65]. Each study collectively reported a significant immediate improvement in mental and physical health-related QOL at six months; however, only physical QOL maintained statistical significance at 12-months post intervention.

Dietary interventions

The impact of dietary patterns and nutritional supplementation on QOL and disability measures in plwMS was assessed in eight studies. [6875] Of the three studies that assessed the impact of fish oil supplementation [7375], only one reported an immediate improvement in the physical composite score of QOL post intervention relative to a control group [74]. The intervention group received a combination of six fish oil capsules per day (198 mg EPA, 132 mg DHA), 400 units of vitamin E, 1 multivitamin, and 500 mg calcium while following a very low fat diet (i.e. < 15% total energy from fat). The control group was fed a low-cholesterol diet (i.e. < 30% total energy from fat), 400 units of vitamin E, 1 multivitamin, 500 mg calcium, and an olive oil supplement as a placebo. No clinical benefit of fish oil supplementation was found in relation to disability measured using the EDSS or the number of new T1 enhanced and hypo-intensive brain lesions [73, 75].
One study evaluated the effect of probiotic intake and reported a significant improvement in EDSS and general health QOL, favouring the intervention [72].
Only one study assessing the impact of vitamin D supplementation found a significant improvement in mental and health-related subscales [69]. The intervention consisted of patients on interferon-beta as their main DMT, supplementing 50,000 IU vitamin D3 every five days for three months. Controls consumed a placebo. Vitamin D supplementation at 20,000 IU was found to have no significant impact on disability measures via the EDSS or relapse rate [68, 71] however, one study of the same supplemental dose did observe a significant decrease in the number of T1 weighted lesions [68]. Control participants were given a placebo and continued with usual care.

Lifestyle and wellbeing

Of the eight studies that assessed lifestyle and/or well-being programs, all were delivered face-to-face, and all reported a significant improvement in QOL, favouring lifestyle self-management courses or exposures [7683]. The most common QOL domains that saw a significant improvement across the eight studies included mental health (n = 7) [76, 7883] and physical health (n = 6) [76, 7882] related QOL. All studies included an intervention or exposure to at least two or more self-management dimensions, and the most common combinations included a dietary (n = 6), exercise (n = 6), and a psychological (emotional, fatigue, stress, coping, support) component (n = 6). In two studies, a group-based self-management workshop, delivered by trained healthcare professionals, reported both a short-term (immediate) and long-term (three years) improvement in QOL [80, 82]. A key finding, however, was the sustained improvement in a majority of QOL subscales, including physical health, mental health, pain, and social and overall QOL, for up to five years post intervention [78, 79]. Only one study [83] used a combination of delivery methods including a face-to-face lifestyle program, followed by three months of accountability telephone calls. Improvements in QOL domains, including pain and mental health, were sustained for the duration of the 8-month intervention period.

Fatigue management

Of the seven studies that assessed the impact of fatigue management programs on QOL [8490], four reported a significant improvement in QOL, favouring the fatigue management course. Five were delivered face-to-face [8587, 89, 90] and two were delivered remotely [84, 88] via teleconference sessions. Of the interventions delivered remotely, both were conducted over a 6-month period however only one reported a significant improvement in physical, vitality and social QOL, favouring the intervention [9193]. The remaining study comprised of a simpler intervention including only three teleconference sessions and four individually tailored counselling phone calls [88].
Of the interventions delivered face-to-face, three reported a significant improvement in domains of QOL [8486]. These three studies ranged from six weeks to three years, however they displayed similar participant characteristics, including mean age of participants around 48 years and disease duration of ~ 9.5 years. The most common QOL domains that saw a significant improvement after fatigue and energy conservation courses included vitality, social, mental health, and physical health-related QOL [8486, 90]. One study that reported no significant improvement after a fatigue intervention accompanied by usual care suggested a longer term follow-up of two years or more may be required to observe a consistent and significant change in QOL [89].

Symptom and medical management

The impact of symptom and medical management on QOL was assessed in three studies [92, 94]. Participants followed either a symptom self-care program [91, 92] or program combining medication management and education [93]. Of these three, one study reported a significant improvement in general health-related QOL after a 12 month intervention period, relative to a control group [91]. This study was delivered via an electronic messaging system between plwMS and their clinicians, to enhance symptom control and management. Controls continued their usual MS care. Of the remaining two observational studies, only one revealed a significant improvement in physical, psychological, social, and environmental QOL after a self-care management course [92]. The remaining study found no significant improvement in QOL after a DMT self-management program; however, they reported a 33.6% significant decrease in relapse rate [93].

Meta-analysis of studies

Only one self-management dimension met the inclusion criteria for a meta-analysis to calculate pooled estimates of the effect of self-management interventions on homogenous disability outcome measures. An additional two meta-analyses were eligible based purely on a homogenous self-management dimension, QOL domain and summary measure. However, the heterogeneity that was created by comparing different study designs would impact the interrelation of results and a decision to exclude these meta-analyses was made by the authors.
  • i. Diet
Five studies, including 286 participants, examined the effect of dietary interventions on disability, using the EDSS [68, 7072, 75]. Aivo et al. [68] Kouchaki et al. [72] and Zandi- Esfahan et al. [75] reported a reduction in EDSS scores following dietary intervention, while Bitarafan et al. [70] and Kampan et al. [71] did not observe a change in EDSS between the intervention and control arms. None of the results were statistically significant.
As demonstrated in Fig. 2, dietary intervention had no statistically significant overall effect on reducing disability as measured by EDSS scores (MD = − 0.13, 95% CI = − 0.31–0.06, Heterogeneity: Tau2 = 0.02, Chi2 = 8.55, df = 4 (P = 0.07); I2 = 53%, test for overall effect Z = 1.35 (P = 0.18). An I2 value of 53% indicated substantial heterogeneity between studies therefore caution is warranted in interpreting these summary estimates. The certainty of the body of evidence by GRADE for dietary interventions was very low, based on downgrading for inconsistency, indirectness, and imprecision. Results of individual GRADE domains are outlined in Additional file 1: data 3.

Risk of bias in individual studies

The RoB for each included study is presented in Additional file 1: data 2. The RoB ranged from low to high across 35 RCT’s. Overall, nine studies had a RoB [44, 52, 62, 65, 68, 71, 73, 79, 88], 11 had some [46, 50, 51, 60, 67, 69, 75, 76, 83, 84, 90] and 15 had a high RoB [38, 43, 45, 5356, 59, 61, 63, 66, 74, 86, 89, 91]. The majority (97%) had a low RoB with selection of the reported results [4346, 48, 50, 51, 5356, 59, 6163, 6676, 83, 86, 88, 89, 91].Thirty-seven percent of studies had some or a high RoB due to the effect of assignment to intervention [38, 43, 46, 50, 53, 55, 59, 61, 63, 66, 89, 90, 91] and 34% of studies had some or a high RoB due to missing outcome data [43, 45, 55, 59, 60, 66, 67, 74, 89, 91].
The RoB in nonrandomised studies of interventions ranged from low to serious. Overall, one study had a low RoB [77], five had a moderate [42, 57, 58, 77, 85] and one had a serious RoB due to intervention classification [49]. All (100%) of studies had a low RoB due to confounding and selective reporting of results. However, 57% (n = 4) [49, 57, 58, 82] studies had a moderate RoB due to measurement of the outcome, and 42% (n = 3) [58, 82, 85] studies had a moderate RoB in the selection of participants.
Based on the NOS, four of the 13-cohort/case control studies were of good quality [41, 78, 87, 93], three were of satisfactory quality [39, 64, 65], and the remaining six were unsatisfactory [37, 52, 79, 80, 83, 92]. Most studies with unsatisfactory scores did not follow appropriate recruitment methods, assessment of outcomes, and/or adequate follow-up of cohorts. The two cross-sectional studies were of satisfactory quality [47, 48]. None of the studies were appraised as having very good quality, mainly because the selected participants were not representative of the exposed cohort and a poor description of outcome assessments. This was possibly due to the nature of the study design and the inability to blind the participants.

Discussion

To the best of our knowledge, this is the first review to systematically explore the effectiveness of lifestyle self-management strategies and/or intervention(s) that influence the health and well-being of plwMS, using a common metric of success. For each of the six self-management dimensions (physical activity and exercise; coping, depression, stress, and emotional management; diet, lifestyle, and well-being; fatigue management; and symptom management), varying impacts on participants’ self-reported QOL and objective measures of disability were reported. Qualitative syntheses of results initially appear promising and are reflected in previous work that has explored lifestyle self-management in MS cohorts [1113]. However, the meta-analysis did not identify any statistically significant effects, which may be a result of the heterogeneity between the included studies and/or due to the small number of studies being meta-analysed [94]. Further to this, the review found that the evidence base for high-quality randomised controlled trials (n = 9) designed to improve QOL and reduce objective measures of disability was limited. Therefore, the overall ability to answer the research question: What are the elements of lifestyle self-management strategies and/or interventions that improve the QOL of plwMS patients, was challenged.
The first key finding was that the eight studies that incorporated multicomponent self-management interventions (i.e. lifestyle and well-being programs) [7683] all reported a significant improvement in self-reported QOL. A reasonable explanation for this finding can be provided through their respective self-management programs that assist participants in gaining skills to control physical symptoms, identify coping strategies to deal with emotional challenges, conserve energy to deal with fatigue, and provide education regarding appropriate dietary choices. As lifestyle is multidimensional, these results were somewhat expected, as the interventions were able to address multiple aspects of care to improve overall QOL. This is consistent with the findings of other studies that have explored multicomponent interventions to improve QOL in chronic disease [95]. Furthermore, these studies used a range of teaching modalities, which have been found to reinforce knowledge comprehension and ensure individual learning styles are addressed [96]. This may have further contributed to the positive improvements in QOL, as self-reported by the participants. Future research should explore the best combinations of self-management dimensions with the greatest effect on improving QOL.
A second key finding was the positive effect of coping, depression, stress, mental health, and/or emotional management strategies in improving the QOL of plwMS [5867]. This result has been described in the literature for other chronic diseases [9799]. It is well established that people with chronic illness find it difficult to cope with the physical and/or emotional challenges of their condition [100]. Furthermore, these challenges have been previously reported to significantly affect QOL due to the impact on one’s ability to work, participate in leisure activities, and engage in social functions. Therefore, it was anticipated that a program equipped with plwMS with the confidence to self-manage the emotions of their diagnosis and develop coping strategies to deal with stress would reduce the burden of their condition and improve QOL. This finding is consistent with a previous systematic review exploring the effectiveness of self-management to improve depression, anxiety and QOL among plwMS [11]. As reported by Kidd et al. effective interventions included principles of the cognitive behavioural theory, in 30% of the studies. One meta-analysis reported that incorporating cognitive behavioural theory in interventions for plwMS is effective in improving QOL domains [11, 101]. The present review has validated this finding.
Fatigue is one of the most common symptoms and burdens approximately 75% of plwMS [102]. It is well established that fatigue is independently associated with impaired QOL in MS, suggesting that recognising and treating fatigue can potentially improve overall life quality [102, 103]. Therefore, interventions encapsulating self-management of fatigue would significantly improve QOL. However, this assumption was only reflected in four out of the seven studies exploring fatigue self-management with interventions ranging from six weeks to three years. One possible reason for these inconsistencies is that behavioural change takes time and, therefore, longer term follow up of two years or more may be required to observe a consistent and significance change in QOL. This was observed in a similar review of fatigue self-management in patients with chronic health conditions such as chronic fatigue syndrome, rheumatoid arthritis, and cancer, suggesting longer follow up times are needed [104].
The pooled estimate of the effect of dietary interventions among the five studies indicated no significant reduction in disability measures reported through the EDSS. According to Higgins et al. [105] the I2 value indicated substantial heterogeneity; therefore, the results should be interpreted with caution. This may be attributed to the substantial variation in the study design, intervention, and methodology among the six included studies. Due to the scarcity of evidence confirming particular food(s) or dietary patterns that are effective in reducing the symptom burden of MS, it was anticipated that no significant effect would be found in this review. These results are consistent with a 2020 Cochrane review, which indicated that there is an insufficient level of evidence to determine whether dietary supplementation and certain dietary patterns have an impact on MS-related outcomes [106]. However, a promising effect of diet on improving QOL domains was observed in these studies. Despite this, high-quality, food-focused clinical trials exploring dietary interventions as a self-management strategy are still warranted.
The reported effect of physical activity on outcome measures was largely inconsistent across 21 studies. In total, 50% (n = 9/18) of studies reported a significant improvement in QOL, and only 38% (n = 3/8) of studies reported a significant improvement in disability measures, such as decreased EDSS score, lesion count, and annualised relapse rate. Previous studies have found that plwMS who participate in regular physical activity report higher QOL [107]. Therefore, if MS participants in these studies were already actively partaking in planned physical activity and exercise, it was anticipated that a ceiling effect was observed [108]. That is, participants were involved in regular physical activity as a self-management strategy prior to the intervention; therefore, there was little opportunity for improvements in QOL to be observed post intervention [108]. Again, future reviews should aim to quantitatively synthesise homogenous results via a meta-analysis to comment on overall effectiveness.
Despite these findings, it is important to note the limitations of this review. Multiple scientific databases were searched using specific terms and truncations. However, the review may have excluded potential relevant studies due to the subjectivity of what constitutes self-management.” Additionally, excluding non-English studies, case studies, review articles, feasibility and pilot studies, protocols and grey literature, conference abstracts, editorials, and monographs may mean that the analysis in the review is limited.
Despite rigorous inclusion criteria, the heterogeneity of the included studies was still evident, therefore, a qualitative synthesis of the included studies was conducted. Several studies recruited only female participants or only individuals with a relapsing–remitting MS phenotype. Multiple QOL questionnaires that differed in their reported domains of QOL were included, making cross-study comparisons difficult. Moreover, a number of studies did not report sufficient outcome and summary measures detailed to their intervention; therefore, quantitative analysis through a meta-analysis was not possible for a majority of the included studies and their respective self-management dimensions. This prevents a definitive answer to the PICO question, without further research.

Conclusion

Multicomponent self-management interventions that incorporate coping, stress, depression, emotional management, multimodal delivery methods, and cognitive behavioural theory principals were common elements of self-management interventions that improved the QOL of plwMS. Dietary intervention had no statistically significant overall effect on reducing MS disability, (P = 0.18). The overall effect of physical activity on these measures was inconsistent.
This review revealed a significant gap in the literature, warranting high-quality, large-scale experimental, and observational studies that address the research question. Therefore, these results should be interpreted with caution, and care should be taken in clinical applications. Heterogeneity continues to limit the ability to pool the effects from a large number of studies. A future review addressing this as evidence-based growth is warranted. The question of the best combination of lifestyle self-management dimensions to improve QOL remains. Therefore, future studies should not only address one dimension, but also explore different combinations of plwMS.

Acknowledgements

The authors would like to acknowledge Emiliana Saffioti for her contribution to the review and screening process.

Declarations

Not applicable.
Not applicable.

Competing interests

YP has received research grants from Multiple Sclerosis Research Australia, a fellowship from Multiple Sclerosis Australia, is a reviewer for a range of multiple sclerosis scientific journals, and has received honoraria from Multiple Sclerosis Research Australia. YP is also a person living with multiple sclerosis. OW declares no conflict of interest.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
2.
Zurück zum Zitat Robertson D, Moreo N. Disease-modifying therapies in multiple sclerosis: overview and treatment considerations. Fed Pract [Internet]. 2016;33(6):28–34.PubMed Robertson D, Moreo N. Disease-modifying therapies in multiple sclerosis: overview and treatment considerations. Fed Pract [Internet]. 2016;33(6):28–34.PubMed
3.
Zurück zum Zitat Boeije HR, Duijnstee MS, Grypdonck MH, Pool A. Encountering the downward phase: biographical work in people with multiple sclerosis living at home. Soc Sci Med [Internet]. 2002;55(6):881–93.CrossRefPubMed Boeije HR, Duijnstee MS, Grypdonck MH, Pool A. Encountering the downward phase: biographical work in people with multiple sclerosis living at home. Soc Sci Med [Internet]. 2002;55(6):881–93.CrossRefPubMed
4.
Zurück zum Zitat Grady PA, Gough LL. Self-management: a comprehensive approach to management of chronic conditions. Am J Public Health [Internet]. 2014;104(8):25–31.CrossRef Grady PA, Gough LL. Self-management: a comprehensive approach to management of chronic conditions. Am J Public Health [Internet]. 2014;104(8):25–31.CrossRef
5.
Zurück zum Zitat Fraser R, Ehde D, Amtmann D, et al. Self-management for people with multiple sclerosis: report from the first international consensus conference. Int J MS Care [Internet]. 2010;15(2):99–106.CrossRef Fraser R, Ehde D, Amtmann D, et al. Self-management for people with multiple sclerosis: report from the first international consensus conference. Int J MS Care [Internet]. 2010;15(2):99–106.CrossRef
6.
Zurück zum Zitat Wagner EH, Austin BT, Davis C, Hindmarsh M, Schaefer J, Bonomi A. Improving chronic illness care: translating evidence into action. Health Aff [Internet]. 2001;20(6):64–78.CrossRef Wagner EH, Austin BT, Davis C, Hindmarsh M, Schaefer J, Bonomi A. Improving chronic illness care: translating evidence into action. Health Aff [Internet]. 2001;20(6):64–78.CrossRef
7.
Zurück zum Zitat Harris MF, Willians AM, Dennis SM, Zwar NA, Powell DG. Chronic disease self management: implementation with and within Australian general practice. MJA [Internet]. 2008;189:10. Harris MF, Willians AM, Dennis SM, Zwar NA, Powell DG. Chronic disease self management: implementation with and within Australian general practice. MJA [Internet]. 2008;189:10.
8.
Zurück zum Zitat Dennis SM, Zwar NA, Griffiths R, Roland M, Hasan I, Powell Davies G, et al. Chronic disease self management in primary care: from evidence to policy. MJA [Internet]. 2008;188:8. Dennis SM, Zwar NA, Griffiths R, Roland M, Hasan I, Powell Davies G, et al. Chronic disease self management in primary care: from evidence to policy. MJA [Internet]. 2008;188:8.
10.
Zurück zum Zitat Clark NM, et al. Self- management of chronic disease by older adults: a review and questions for research. Sage J. 1991;3(1):3–27. Clark NM, et al. Self- management of chronic disease by older adults: a review and questions for research. Sage J. 1991;3(1):3–27.
11.
Zurück zum Zitat Kidd T, et al. A systematic review of the effectiveness of self-management interventions in people with multiple sclerosis at improving depression, anxiety and quality of life. PLoS ONE [Internet]. 2017;12(10):e0185931.CrossRefPubMed Kidd T, et al. A systematic review of the effectiveness of self-management interventions in people with multiple sclerosis at improving depression, anxiety and quality of life. PLoS ONE [Internet]. 2017;12(10):e0185931.CrossRefPubMed
12.
Zurück zum Zitat Rae-Grant AD, Turner AP, Sloan A, Miller D, Hunziker J, Haselkorn JK. Self-management in neurological disorders: systematic review of the literature and potential interventions in multiple sclerosis care. J Rehabil Res Dev [Internet]. 2011;48:1087–100.CrossRefPubMed Rae-Grant AD, Turner AP, Sloan A, Miller D, Hunziker J, Haselkorn JK. Self-management in neurological disorders: systematic review of the literature and potential interventions in multiple sclerosis care. J Rehabil Res Dev [Internet]. 2011;48:1087–100.CrossRefPubMed
13.
Zurück zum Zitat Yamaguchi S, Yatsushiro R. Significance and potential of self-management research for HTLV-1 associated myelopathy: review of self-management for people with multiple sclerosis. J Rural Med [Internet]. 2019;14(1):7–25.CrossRefPubMed Yamaguchi S, Yatsushiro R. Significance and potential of self-management research for HTLV-1 associated myelopathy: review of self-management for people with multiple sclerosis. J Rural Med [Internet]. 2019;14(1):7–25.CrossRefPubMed
14.
Zurück zum Zitat Higginson IJ, Carr AJ. Measuring quality of life: using quality of life measures in the clinical setting. BMJ [Internet]. 2001;322(7297):1297–300.CrossRefPubMed Higginson IJ, Carr AJ. Measuring quality of life: using quality of life measures in the clinical setting. BMJ [Internet]. 2001;322(7297):1297–300.CrossRefPubMed
15.
Zurück zum Zitat Mitchell AJ, Benito-León J, González JM, Rivera-Navarro J. Quality of life and its assessment in multiple sclerosis: integrating physical and psychological components of wellbeing. Lancet Neurol [Internet]. 2005;4(9):556–66.CrossRefPubMed Mitchell AJ, Benito-León J, González JM, Rivera-Navarro J. Quality of life and its assessment in multiple sclerosis: integrating physical and psychological components of wellbeing. Lancet Neurol [Internet]. 2005;4(9):556–66.CrossRefPubMed
16.
Zurück zum Zitat Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA. Cochrane Handbook for Systematic Reviews of Interventions [Internet]. 2020 [cited 2021 Feb 9]; version 6.1 Available from: www.training.cochrane.org/handbook. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA. Cochrane Handbook for Systematic Reviews of Interventions [Internet]. 2020 [cited 2021 Feb 9]; version 6.1 Available from: www.​training.​cochrane.​org/​handbook.
17.
Zurück zum Zitat Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffman TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ [Internet]. 2021;372(71). Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffman TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ [Internet]. 2021;372(71).
19.
Zurück zum Zitat Stewart L, Moher D, Shekelle P. Why prospective registration of systematic reviews makes sense. Syst Rev [Internet]. 2012;1(7):1–4.PubMed Stewart L, Moher D, Shekelle P. Why prospective registration of systematic reviews makes sense. Syst Rev [Internet]. 2012;1(7):1–4.PubMed
22.
Zurück zum Zitat Baumstarck K, Boyer L, Boucekine M, Michel P, Pelletier J, Auquier P. Measuring the quality of life in patients with multiple sclerosis in clinical practice: a necessary challenge Mult Scler Int [Internet]. 2013;524894 Baumstarck K, Boyer L, Boucekine M, Michel P, Pelletier J, Auquier P. Measuring the quality of life in patients with multiple sclerosis in clinical practice: a necessary challenge Mult Scler Int [Internet]. 2013;524894
24.
Zurück zum Zitat Meyer-Moock S, Feng YS, Maeurer M, Dippel FW, Kohlmann T. Systematic literature review and validity evaluation of the expanded disability status scale (EDSS) and the multiple sclerosis functional composite (MSFC) in patients with multiple sclerosis. BMC Neurol [Internet]. 2014;14:58.CrossRefPubMed Meyer-Moock S, Feng YS, Maeurer M, Dippel FW, Kohlmann T. Systematic literature review and validity evaluation of the expanded disability status scale (EDSS) and the multiple sclerosis functional composite (MSFC) in patients with multiple sclerosis. BMC Neurol [Internet]. 2014;14:58.CrossRefPubMed
25.
Zurück zum Zitat Learmonth YC, Motl RW, Sandroff BM, et al. Validation of patient determined disease steps (PDDS) scale scores in persons with multiple sclerosis. BMC Neurol [Internet]. 2013;13:37.CrossRefPubMed Learmonth YC, Motl RW, Sandroff BM, et al. Validation of patient determined disease steps (PDDS) scale scores in persons with multiple sclerosis. BMC Neurol [Internet]. 2013;13:37.CrossRefPubMed
26.
Zurück zum Zitat Van Munster CEP, Uitdehaag BM. Outcome measures in clinical trials for multiple sclerosis. CNS Drugs [Internet]. 2017;31:217–36.CrossRefPubMed Van Munster CEP, Uitdehaag BM. Outcome measures in clinical trials for multiple sclerosis. CNS Drugs [Internet]. 2017;31:217–36.CrossRefPubMed
27.
Zurück zum Zitat Rosen L, Suhami R. The art and science of study identification: a comparative analysis of two systematic reviews. BMC Med Res Methodol [Internet]. 2016;16:24.CrossRefPubMed Rosen L, Suhami R. The art and science of study identification: a comparative analysis of two systematic reviews. BMC Med Res Methodol [Internet]. 2016;16:24.CrossRefPubMed
28.
Zurück zum Zitat Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ Res Methods Rep [Internet]. 2017;358. Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ Res Methods Rep [Internet]. 2017;358.
29.
Zurück zum Zitat Higgins JPT, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. J R Stat Soc [Internet] Ser A Stat Soc. 2009;172:137–59.CrossRefPubMed Higgins JPT, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. J R Stat Soc [Internet] Ser A Stat Soc. 2009;172:137–59.CrossRefPubMed
31.
Zurück zum Zitat Higgins JPT, Savovic J, Page MJ, Sterne JAC. Revised Cochrane risk- of- bias tool for randomised trials (RoB 2) SHORT VERSION (CRIBSHEET) [Internet]. 2019 Higgins JPT, Savovic J, Page MJ, Sterne JAC. Revised Cochrane risk- of- bias tool for randomised trials (RoB 2) SHORT VERSION (CRIBSHEET) [Internet]. 2019
32.
Zurück zum Zitat Sterne JAC, Hernan MA, McAleenan A, Reeves BC, Higgins JPT. Chapter 25: Assessing risk of bias in non- randomised study [Internet]. Cochrane Handbook for Systematic Reviews of Interventions version 6.2. 2021. Sterne JAC, Hernan MA, McAleenan A, Reeves BC, Higgins JPT. Chapter 25: Assessing risk of bias in non- randomised study [Internet]. Cochrane Handbook for Systematic Reviews of Interventions version 6.2. 2021.
33.
Zurück zum Zitat Wells GA, O’Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Hosp Res Inst [Internet]. 2021 [Cited 2021 9 August]. Wells GA, O’Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Hosp Res Inst [Internet]. 2021 [Cited 2021 9 August].
34.
Zurück zum Zitat Modesti PA, Reboldi G, Cappuccio FP, Agyemang C, Remuzzi G, et al. Panethnic differences in blood pressure in europe: a systematic review and meta-analysis. PloS One [Internet]. 2016;11(1):e0147601.CrossRefPubMed Modesti PA, Reboldi G, Cappuccio FP, Agyemang C, Remuzzi G, et al. Panethnic differences in blood pressure in europe: a systematic review and meta-analysis. PloS One [Internet]. 2016;11(1):e0147601.CrossRefPubMed
35.
Zurück zum Zitat Takahashi N, Hashizume M. A systematic review of the influence of occupational organophosphate pesticides exposure on neurological impairment. BMJ Open [Internet]. 2014;4:004798. Takahashi N, Hashizume M. A systematic review of the influence of occupational organophosphate pesticides exposure on neurological impairment. BMJ Open [Internet]. 2014;4:004798.
36.
Zurück zum Zitat Schünemann HJ, Higgins JPT, Vist GE, Glasziou P, Akl EA, Skoetz N, et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook. Schünemann HJ, Higgins JPT, Vist GE, Glasziou P, Akl EA, Skoetz N, et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.​training.​cochrane.​org/​handbook.
37.
Zurück zum Zitat Beatus J, O’Neill JK, Townsend T, Robrecht K. The effect of a one-week retreat on self-esteem, quality of life, and functional ability for persons with multiple sclerosis. Neurol Rep [Internet]. 2002;26(3):154–9.CrossRef Beatus J, O’Neill JK, Townsend T, Robrecht K. The effect of a one-week retreat on self-esteem, quality of life, and functional ability for persons with multiple sclerosis. Neurol Rep [Internet]. 2002;26(3):154–9.CrossRef
38.
Zurück zum Zitat Carter A, Daley A, Humphreys L, Snowdon N, Woodroofe N, Petty J, et al. Pragmatic intervention for increasing self-directed exercise behaviour and improving important health outcomes in people with multiple sclerosis: a randomised controlled trial. Mult Scler [Internet]. 2014;20(8):1112–22.CrossRefPubMed Carter A, Daley A, Humphreys L, Snowdon N, Woodroofe N, Petty J, et al. Pragmatic intervention for increasing self-directed exercise behaviour and improving important health outcomes in people with multiple sclerosis: a randomised controlled trial. Mult Scler [Internet]. 2014;20(8):1112–22.CrossRefPubMed
39.
Zurück zum Zitat D’Hooghe MB, Feys P, Deltour S, Van de Putte I, De Meue J, Kos D, et al. Impact of a 5-day expedition to machu picchu on persons with multiple sclerosis. Mult Scler Int [Internet]. 2014;2014: 761210.PubMed D’Hooghe MB, Feys P, Deltour S, Van de Putte I, De Meue J, Kos D, et al. Impact of a 5-day expedition to machu picchu on persons with multiple sclerosis. Mult Scler Int [Internet]. 2014;2014: 761210.PubMed
40.
Zurück zum Zitat Fasczewski KS, Gill DL, Rothberger SM. Physical activity motivation and benefits in people with multiple sclerosis. Disabil Rehabil [Internet]. 2018;40(13):1517–23.CrossRefPubMed Fasczewski KS, Gill DL, Rothberger SM. Physical activity motivation and benefits in people with multiple sclerosis. Disabil Rehabil [Internet]. 2018;40(13):1517–23.CrossRefPubMed
41.
Zurück zum Zitat Fasczewski KS, Garner LM, Clark LA, Michels HS, Migliarese SJ. Medical Therapeutic Yoga for multiple sclerosis: examining self-efficacy for physical activity, motivation for physical activity, and quality of life outcomes. Disabil Rehabil [Internet]. 2020:1–8. Fasczewski KS, Garner LM, Clark LA, Michels HS, Migliarese SJ. Medical Therapeutic Yoga for multiple sclerosis: examining self-efficacy for physical activity, motivation for physical activity, and quality of life outcomes. Disabil Rehabil [Internet]. 2020:1–8.
42.
Zurück zum Zitat Feys P, Tytgat K, Gijbels D, De Groote L, Baert I, Van Asch P. Effects of an 1-day education program on physical functioning, activity and quality of life in community living persons with multiple sclerosis. NeuroRehabilitation [Internet]. 2013;33(3):439–48.CrossRefPubMed Feys P, Tytgat K, Gijbels D, De Groote L, Baert I, Van Asch P. Effects of an 1-day education program on physical functioning, activity and quality of life in community living persons with multiple sclerosis. NeuroRehabilitation [Internet]. 2013;33(3):439–48.CrossRefPubMed
43.
Zurück zum Zitat Flachenecker P, Bures AK, Gawlik A, Weiland AC, Kuld S, Gusowski K, et al. Efficacy of an internet-based program to promote physical activity and exercise after inpatient rehabilitation in persons with multiple sclerosis: a randomized, single-blind, controlled study. Int J Environ Res Public Health [Internet]. 2020;17(12):4544.CrossRefPubMed Flachenecker P, Bures AK, Gawlik A, Weiland AC, Kuld S, Gusowski K, et al. Efficacy of an internet-based program to promote physical activity and exercise after inpatient rehabilitation in persons with multiple sclerosis: a randomized, single-blind, controlled study. Int J Environ Res Public Health [Internet]. 2020;17(12):4544.CrossRefPubMed
44.
Zurück zum Zitat Khan F, Pallant JF, Brand C, Kilpatrick TJ, Khan F, Pallant JF, et al. Effectiveness of rehabilitation intervention in persons with multiple sclerosis: a randomised controlled trial. J Neurol Neurosurg Psychiatry [Internet]. 2008;79(11):1230–5.CrossRefPubMed Khan F, Pallant JF, Brand C, Kilpatrick TJ, Khan F, Pallant JF, et al. Effectiveness of rehabilitation intervention in persons with multiple sclerosis: a randomised controlled trial. J Neurol Neurosurg Psychiatry [Internet]. 2008;79(11):1230–5.CrossRefPubMed
45.
Zurück zum Zitat Kjølhede T, Siemonsen S, Wenzel D, Stellmann JP, Ringgaard S, Pedersen BG, et al. Can resistance training impact MRI outcomes in relapsing-remitting multiple sclerosis? Mult Scler [Internet]. 2018;24(10):1356–65.CrossRefPubMed Kjølhede T, Siemonsen S, Wenzel D, Stellmann JP, Ringgaard S, Pedersen BG, et al. Can resistance training impact MRI outcomes in relapsing-remitting multiple sclerosis? Mult Scler [Internet]. 2018;24(10):1356–65.CrossRefPubMed
46.
Zurück zum Zitat Langeskov-Christensen M, Grøndahl Hvid L, Nygaard MKE, Ringgaard S, Jensen HB, Nielsen HH, et al. Efficacy of high-intensity aerobic exercise on brain mri measures in multiple sclerosis. Neurology [Internet]. 2021;96(2):e203–13.CrossRefPubMed Langeskov-Christensen M, Grøndahl Hvid L, Nygaard MKE, Ringgaard S, Jensen HB, Nielsen HH, et al. Efficacy of high-intensity aerobic exercise on brain mri measures in multiple sclerosis. Neurology [Internet]. 2021;96(2):e203–13.CrossRefPubMed
47.
Zurück zum Zitat Motl RW, McAuley E, Snook EM. Physical activity and quality of life in multiple sclerosis: possible roles of social support, self-efficacy, and functional limitations. Rehabil Psychol [Internet]. 2007;52(2):143–51.CrossRef Motl RW, McAuley E, Snook EM. Physical activity and quality of life in multiple sclerosis: possible roles of social support, self-efficacy, and functional limitations. Rehabil Psychol [Internet]. 2007;52(2):143–51.CrossRef
48.
Zurück zum Zitat Motl RW, McAuley E. Pathways between physical activity and quality of life in adults with multiple sclerosis. Health Psychol [Internet]. 2009;28(6):682–9.CrossRefPubMed Motl RW, McAuley E. Pathways between physical activity and quality of life in adults with multiple sclerosis. Health Psychol [Internet]. 2009;28(6):682–9.CrossRefPubMed
49.
Zurück zum Zitat Motl RW, McAuley E, Wynn D, Vollmer T. Lifestyle physical activity and walking impairment over time in relapsing-remitting multiple sclerosis: results from a panel study. Am J Phys Med Rehabil [Internet]. 2011;90(5):372–9.CrossRefPubMed Motl RW, McAuley E, Wynn D, Vollmer T. Lifestyle physical activity and walking impairment over time in relapsing-remitting multiple sclerosis: results from a panel study. Am J Phys Med Rehabil [Internet]. 2011;90(5):372–9.CrossRefPubMed
50.
Zurück zum Zitat Mutluay FK, Demir R, Ozyilmaz S, Caglar AT, Altintas A, Gurses HN. Breathing-enhanced upper extremity exercises for patients with multiple sclerosis. Clin Rehabil [Internet]. 2007;21(7):595–602.CrossRefPubMed Mutluay FK, Demir R, Ozyilmaz S, Caglar AT, Altintas A, Gurses HN. Breathing-enhanced upper extremity exercises for patients with multiple sclerosis. Clin Rehabil [Internet]. 2007;21(7):595–602.CrossRefPubMed
51.
Zurück zum Zitat Petjan JH, Gappmaier E, White AT, Spencer MK, Mino L, Hicks RW. Impact of aerobic training on fitness and quality of life in multiple sclerosis. Ann Neurol [Internet]. 1996;39:432–41.CrossRef Petjan JH, Gappmaier E, White AT, Spencer MK, Mino L, Hicks RW. Impact of aerobic training on fitness and quality of life in multiple sclerosis. Ann Neurol [Internet]. 1996;39:432–41.CrossRef
52.
Zurück zum Zitat Pilutti LA, Dlugonski D, Sandroff BM, Klaren R, Motl RW. Randomized controlled trial of a behavioral intervention targeting symptoms and physical activity in multiple sclerosis. Mult Scler [Internet]. 2014;20(5):594–601.CrossRefPubMed Pilutti LA, Dlugonski D, Sandroff BM, Klaren R, Motl RW. Randomized controlled trial of a behavioral intervention targeting symptoms and physical activity in multiple sclerosis. Mult Scler [Internet]. 2014;20(5):594–601.CrossRefPubMed
53.
Zurück zum Zitat Oken BS, Kishiyama S, Zajdel D, Bourdette MD, Carlsen AB, Haas DC. Randomised controlled trial of yoga and exercise in multiple sclerosis. Neurology [Internet]. 2004;62:2058–64.CrossRefPubMed Oken BS, Kishiyama S, Zajdel D, Bourdette MD, Carlsen AB, Haas DC. Randomised controlled trial of yoga and exercise in multiple sclerosis. Neurology [Internet]. 2004;62:2058–64.CrossRefPubMed
54.
Zurück zum Zitat Sangelaji B, Nabavi SM, Estebsari F, Banshi MR, Rashidian H, Jamshidi E, et al. Effect of combination exercise therapy on walking distance, postural balance, fatigue and quality of life in multiple sclerosis patients: a clinical trial study. Iran Red Crescent Med J [Internet]. 2014;16(6): e17173.PubMed Sangelaji B, Nabavi SM, Estebsari F, Banshi MR, Rashidian H, Jamshidi E, et al. Effect of combination exercise therapy on walking distance, postural balance, fatigue and quality of life in multiple sclerosis patients: a clinical trial study. Iran Red Crescent Med J [Internet]. 2014;16(6): e17173.PubMed
55.
Zurück zum Zitat Savšek L, Stergar T, Strojnik V, Ihan A, Koren A, Špiclin Ž, et al. Impact of aerobic exercise on clinical and magnetic resonance imaging biomarkers in persons with multiple sclerosis: an exploratory randomized controlled trial. J Rehabil Med [Internet]. 2021;53(4):jrm00178.CrossRefPubMed Savšek L, Stergar T, Strojnik V, Ihan A, Koren A, Špiclin Ž, et al. Impact of aerobic exercise on clinical and magnetic resonance imaging biomarkers in persons with multiple sclerosis: an exploratory randomized controlled trial. J Rehabil Med [Internet]. 2021;53(4):jrm00178.CrossRefPubMed
56.
Zurück zum Zitat Sutherland G, Andersen MB, Stoove MA. Can aerobic exercise training affect health- realted quality of life for people with multiple sclerosis? J Sport Exerc Psych [Internet]. 2001;23:122–35.CrossRef Sutherland G, Andersen MB, Stoove MA. Can aerobic exercise training affect health- realted quality of life for people with multiple sclerosis? J Sport Exerc Psych [Internet]. 2001;23:122–35.CrossRef
57.
Zurück zum Zitat Vasudevan S, Devulapally S, Chirravuri K, Elangovan V, Kesavan N. Personalized yoga therapy for multiple sclerosis: effect on symptom management and quality of life. Int J Yoga Therap [Internet]. 2020. Vasudevan S, Devulapally S, Chirravuri K, Elangovan V, Kesavan N. Personalized yoga therapy for multiple sclerosis: effect on symptom management and quality of life. Int J Yoga Therap [Internet]. 2020.
58.
Zurück zum Zitat Abolghasemi A, Farhand S, Taherifard M, Kiamarsi A, Saharkhix- AA. The effect of supportive expressive therapy on hope and quality of life in patients with MS. Psych Psycho [Internet]. 2016;4:20–7. Abolghasemi A, Farhand S, Taherifard M, Kiamarsi A, Saharkhix- AA. The effect of supportive expressive therapy on hope and quality of life in patients with MS. Psych Psycho [Internet]. 2016;4:20–7.
59.
Zurück zum Zitat Besharat M, Nabavi SM, Geranmayepour S, Morsali D, Haghani S. Mindfulness- based stress reduction program: the effect of a novel psycho- interventional method on quality of life, mental health and self- efficacy in female patients with multiple sclerosis. A randomised controlled trial. J Biol [Internet]. 2017;6(11):211–5. Besharat M, Nabavi SM, Geranmayepour S, Morsali D, Haghani S. Mindfulness- based stress reduction program: the effect of a novel psycho- interventional method on quality of life, mental health and self- efficacy in female patients with multiple sclerosis. A randomised controlled trial. J Biol [Internet]. 2017;6(11):211–5.
60.
Zurück zum Zitat Ehde DM, Elzea JL, Verrall AM, Gibbons LE, Smith AE, Amtmann D. Efficacy of a telephone-delivered self-management intervention for persons with multiple sclerosis: a randomized controlled trial with a one-year follow-up. Arch Phys Med Rehabil [Internet]. 2015;96(11):1945–58.CrossRefPubMed Ehde DM, Elzea JL, Verrall AM, Gibbons LE, Smith AE, Amtmann D. Efficacy of a telephone-delivered self-management intervention for persons with multiple sclerosis: a randomized controlled trial with a one-year follow-up. Arch Phys Med Rehabil [Internet]. 2015;96(11):1945–58.CrossRefPubMed
61.
Zurück zum Zitat Grossman P, Kappos L, Gensicke H, D’Souza M, Mohr DC, Penner LK. MS quality of life, depression and fatigue improve after mindfulness training. Neurology [Internet]. 2010;75(13):1141–9.CrossRefPubMed Grossman P, Kappos L, Gensicke H, D’Souza M, Mohr DC, Penner LK. MS quality of life, depression and fatigue improve after mindfulness training. Neurology [Internet]. 2010;75(13):1141–9.CrossRefPubMed
62.
Zurück zum Zitat Graziano F, Calandri E, Borghi M, Bonino S. The effects of a group-based cognitive behavioral therapy on people with multiple sclerosis: a randomized controlled trial. Clin Rehabil [Internet]. 2014;28(3):264–74.CrossRefPubMed Graziano F, Calandri E, Borghi M, Bonino S. The effects of a group-based cognitive behavioral therapy on people with multiple sclerosis: a randomized controlled trial. Clin Rehabil [Internet]. 2014;28(3):264–74.CrossRefPubMed
63.
Zurück zum Zitat Hart S, Fonareva I, Merluzzi N, Mohr D. Treatment for depression and its relationship to improvement in quality of life and psychological well-being in multiple sclerosis patients. Qual Life Res [Internet]. 2005;14:695–703.CrossRefPubMed Hart S, Fonareva I, Merluzzi N, Mohr D. Treatment for depression and its relationship to improvement in quality of life and psychological well-being in multiple sclerosis patients. Qual Life Res [Internet]. 2005;14:695–703.CrossRefPubMed
64.
Zurück zum Zitat Jongen PJ, Ruimschotel R, Heerings M, Hussaarts A, Duyverman L, van der Zande A, et al. Improved self-efficacy in persons with relapsing remitting multiple sclerosis after an intensive social cognitive wellness program with participation of support partners: a 6-months observational study. Health Qual Life Outcomes [Internet]. 2014;12(1):40.CrossRefPubMed Jongen PJ, Ruimschotel R, Heerings M, Hussaarts A, Duyverman L, van der Zande A, et al. Improved self-efficacy in persons with relapsing remitting multiple sclerosis after an intensive social cognitive wellness program with participation of support partners: a 6-months observational study. Health Qual Life Outcomes [Internet]. 2014;12(1):40.CrossRefPubMed
65.
Zurück zum Zitat Jongen PJ, Heerings M, Ruimschotel R, Hussaarts A, Duyverman L, van der Zande A, et al. Intensive social cognitive treatment (can do treatment) with participation of support partners in persons with relapsing remitting multiple sclerosis: observation of improved self-efficacy, quality of life, anxiety and depression 1 year later. BMC Res Notes [Internet]. 2016;9:375.CrossRefPubMed Jongen PJ, Heerings M, Ruimschotel R, Hussaarts A, Duyverman L, van der Zande A, et al. Intensive social cognitive treatment (can do treatment) with participation of support partners in persons with relapsing remitting multiple sclerosis: observation of improved self-efficacy, quality of life, anxiety and depression 1 year later. BMC Res Notes [Internet]. 2016;9:375.CrossRefPubMed
66.
Zurück zum Zitat Jongen PJ, van Mastrigt GA, Heerings M, Visser LH, Ruimschotel RP, Hussaarts A, et al. Effect of an intensive 3-day social cognitive treatment (can do treatment) on control self-efficacy in patients with relapsing remitting multiple sclerosis and low disability: a single-centre randomized controlled trial. PLoS One [Internet]. 2019;14(10):e0223482.CrossRefPubMed Jongen PJ, van Mastrigt GA, Heerings M, Visser LH, Ruimschotel RP, Hussaarts A, et al. Effect of an intensive 3-day social cognitive treatment (can do treatment) on control self-efficacy in patients with relapsing remitting multiple sclerosis and low disability: a single-centre randomized controlled trial. PLoS One [Internet]. 2019;14(10):e0223482.CrossRefPubMed
67.
Zurück zum Zitat Lincoln NB, Yuill F, Holmes J, Drummond AE, Constantinescu CS, Armstrong S, et al. Evaluation of an adjustment group for people with multiple sclerosis and low mood: a randomized controlled trial. Mult Scler [Internet]. 2011;17(10):1250–7.CrossRefPubMed Lincoln NB, Yuill F, Holmes J, Drummond AE, Constantinescu CS, Armstrong S, et al. Evaluation of an adjustment group for people with multiple sclerosis and low mood: a randomized controlled trial. Mult Scler [Internet]. 2011;17(10):1250–7.CrossRefPubMed
68.
Zurück zum Zitat Aivo J, Lindsrom BM, Soilu-Hanninen M. A randomised, double- blind, placebo- controlled trial with vitamin D3 in MS: subgroup analysis of patients with baseline disease activity despite interferon treatment. MS Int [Internet]. 2012;2012:802796. Aivo J, Lindsrom BM, Soilu-Hanninen M. A randomised, double- blind, placebo- controlled trial with vitamin D3 in MS: subgroup analysis of patients with baseline disease activity despite interferon treatment. MS Int [Internet]. 2012;2012:802796.
69.
Zurück zum Zitat Ashtari F, Toghianifar N, Zarkesh-Esfahani SH, Mansourian M. High dose Vitamin D intake and quality of life in relapsing-remitting multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. Neurol Res [Internet]. 2016;38(10):888–92.CrossRefPubMed Ashtari F, Toghianifar N, Zarkesh-Esfahani SH, Mansourian M. High dose Vitamin D intake and quality of life in relapsing-remitting multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. Neurol Res [Internet]. 2016;38(10):888–92.CrossRefPubMed
70.
Zurück zum Zitat Bitarafan S, Saboor-Yaraghi A, Sahraian MA, Nafissi S, Togha M, Beladi Moghadam N, et al. Impact of vitamin A Supplementation on disease progression in patients with multiple sclerosis. Arch Iran Med [Internet]. 2015;18(7):435–40.PubMed Bitarafan S, Saboor-Yaraghi A, Sahraian MA, Nafissi S, Togha M, Beladi Moghadam N, et al. Impact of vitamin A Supplementation on disease progression in patients with multiple sclerosis. Arch Iran Med [Internet]. 2015;18(7):435–40.PubMed
71.
Zurück zum Zitat Kampman MT, Steffensen LH, Mellgren SI, Jørgensen L. Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial. Mult Scler [Internet]. 2012;18(8):1144–51.CrossRefPubMed Kampman MT, Steffensen LH, Mellgren SI, Jørgensen L. Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial. Mult Scler [Internet]. 2012;18(8):1144–51.CrossRefPubMed
72.
Zurück zum Zitat Kouchaki E, Tamtaji Salami M, Bahmani F, Daneshvar Kakhaki R, Akbari E, Tajabadi-Ebrahimi M, et al. Clinical and metabolic response to probiotic supplementation in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled trial. Clin Nutr [Internet]. 2017;36(5):1245–9.CrossRefPubMed Kouchaki E, Tamtaji Salami M, Bahmani F, Daneshvar Kakhaki R, Akbari E, Tajabadi-Ebrahimi M, et al. Clinical and metabolic response to probiotic supplementation in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled trial. Clin Nutr [Internet]. 2017;36(5):1245–9.CrossRefPubMed
73.
Zurück zum Zitat Torkildsen O, Wergeland S, Bakke S, Beiske AG, Bjerve KS, Hovdal H, et al. ω-3 fatty acid treatment in multiple sclerosis (OFAMS Study): a randomized, double-blind, placebo-controlled trial. Arch Neurol [Internet]. 2012;69(8):1044–51.PubMed Torkildsen O, Wergeland S, Bakke S, Beiske AG, Bjerve KS, Hovdal H, et al. ω-3 fatty acid treatment in multiple sclerosis (OFAMS Study): a randomized, double-blind, placebo-controlled trial. Arch Neurol [Internet]. 2012;69(8):1044–51.PubMed
74.
Zurück zum Zitat Weinstock-Guttman B, Baier M, Park Y, Feichter J, Lee-Kwen P, Gallagher E, et al. Low fat dietary intervention with omega-3 fatty acid supplementation in multiple sclerosis patients. Prostaglandins Leukot Essent Fatty Acids [Internet]. 2005;73(5):397–404.CrossRefPubMed Weinstock-Guttman B, Baier M, Park Y, Feichter J, Lee-Kwen P, Gallagher E, et al. Low fat dietary intervention with omega-3 fatty acid supplementation in multiple sclerosis patients. Prostaglandins Leukot Essent Fatty Acids [Internet]. 2005;73(5):397–404.CrossRefPubMed
75.
Zurück zum Zitat Zandi-Esfahan S, Fazeli M, Shaygannejad V, Hasheminia J, Badihian S, Aghayerashti M, et al. Evaluating the effect of adding fish oil to Fingolimod on TNF-α, IL1β, IL6, and IFN-γ in patients with relapsing-remitting multiple sclerosis: a double-blind randomized placebo-controlled trial. Clin Neurol Neurosurg [Internet]. 2017;163:173–8.CrossRefPubMed Zandi-Esfahan S, Fazeli M, Shaygannejad V, Hasheminia J, Badihian S, Aghayerashti M, et al. Evaluating the effect of adding fish oil to Fingolimod on TNF-α, IL1β, IL6, and IFN-γ in patients with relapsing-remitting multiple sclerosis: a double-blind randomized placebo-controlled trial. Clin Neurol Neurosurg [Internet]. 2017;163:173–8.CrossRefPubMed
76.
Zurück zum Zitat Ennis M, Thain J, Boggild M, Baker GA, Young CA. A randomized controlled trial of a health promotion education programme for people with multiple sclerosis. Clin Rehabil [Internet]. 2006;20(9):783–92.CrossRefPubMed Ennis M, Thain J, Boggild M, Baker GA, Young CA. A randomized controlled trial of a health promotion education programme for people with multiple sclerosis. Clin Rehabil [Internet]. 2006;20(9):783–92.CrossRefPubMed
77.
Zurück zum Zitat Feicke J, Spörhase U, Köhler J, Busch C, Wirtz M. A multicenter, prospective, quasi-experimental evaluation study of a patient education program to foster multiple sclerosis self-management competencies. Patient Educ Couns [Internet]. 2014;97(3):361–9.CrossRefPubMed Feicke J, Spörhase U, Köhler J, Busch C, Wirtz M. A multicenter, prospective, quasi-experimental evaluation study of a patient education program to foster multiple sclerosis self-management competencies. Patient Educ Couns [Internet]. 2014;97(3):361–9.CrossRefPubMed
78.
Zurück zum Zitat Hadgkiss EJ, Jelinek GA, Weiland TJ, Rumbold G, Mackinlay CA, Gutbrod S, et al. Health-related quality of life outcomes at 1 and 5 years after a residential retreat promoting lifestyle modification for people with multiple sclerosis. Neurol Sci [Internet]. 2013;34(2):187–95.CrossRefPubMed Hadgkiss EJ, Jelinek GA, Weiland TJ, Rumbold G, Mackinlay CA, Gutbrod S, et al. Health-related quality of life outcomes at 1 and 5 years after a residential retreat promoting lifestyle modification for people with multiple sclerosis. Neurol Sci [Internet]. 2013;34(2):187–95.CrossRefPubMed
79.
Zurück zum Zitat Li MP, Jelinek GA, Weiland TJ, Mackinlay CA, Dye S, Gawler I. Effect of a residential retreat promoting lifestyle modifications on health-related quality of life in people with multiple sclerosis. Qual Prim Care [Internet]. 2010;18(6):379–89.PubMed Li MP, Jelinek GA, Weiland TJ, Mackinlay CA, Dye S, Gawler I. Effect of a residential retreat promoting lifestyle modifications on health-related quality of life in people with multiple sclerosis. Qual Prim Care [Internet]. 2010;18(6):379–89.PubMed
80.
Zurück zum Zitat Marck CH, De Livera AM, Brown CR, Neate SL, Taylor KL, Weiland TJ, et al. Health outcomes and adherence to a healthy lifestyle after a multimodal intervention in people with multiple sclerosis: three year follow-up. PLoS One [Internet]. 2018;13(5): e0197759.CrossRefPubMed Marck CH, De Livera AM, Brown CR, Neate SL, Taylor KL, Weiland TJ, et al. Health outcomes and adherence to a healthy lifestyle after a multimodal intervention in people with multiple sclerosis: three year follow-up. PLoS One [Internet]. 2018;13(5): e0197759.CrossRefPubMed
81.
Zurück zum Zitat Ng A, Kennedy P, Hutchinson B, Ingram A, Vondrell S, Goodman T, et al. Self-efficacy and health status improve after a wellness program in persons with multiple sclerosis. Disabil Rehabil [Internet]. 2013;35(12):1039–44.CrossRefPubMed Ng A, Kennedy P, Hutchinson B, Ingram A, Vondrell S, Goodman T, et al. Self-efficacy and health status improve after a wellness program in persons with multiple sclerosis. Disabil Rehabil [Internet]. 2013;35(12):1039–44.CrossRefPubMed
82.
Zurück zum Zitat Sahebalzamani M, Zamiri M, Rashvand F. The effects of self-care training on quality of life in patients with multiple sclerosis. Iran J Nurs Midwifery Res [Internet]. 2012;17(1):7–11.PubMed Sahebalzamani M, Zamiri M, Rashvand F. The effects of self-care training on quality of life in patients with multiple sclerosis. Iran J Nurs Midwifery Res [Internet]. 2012;17(1):7–11.PubMed
83.
Zurück zum Zitat Stuifbergen AK, Becker H, Blozis S, Timmerman G, Kullberg V. A randomized clinical trial of a wellness intervention for women with multiple sclerosis. Arch Phys Med Rehabil [Internet]. 2003;84(4):467–76.CrossRefPubMed Stuifbergen AK, Becker H, Blozis S, Timmerman G, Kullberg V. A randomized clinical trial of a wellness intervention for women with multiple sclerosis. Arch Phys Med Rehabil [Internet]. 2003;84(4):467–76.CrossRefPubMed
84.
Zurück zum Zitat Finlayson M, Preissner K, Cho C, Plow M. Randomized trial of a teleconference-delivered fatigue management program for people with multiple sclerosis. Mult Scler [Internet]. 2011;17(9):1130–40.CrossRefPubMed Finlayson M, Preissner K, Cho C, Plow M. Randomized trial of a teleconference-delivered fatigue management program for people with multiple sclerosis. Mult Scler [Internet]. 2011;17(9):1130–40.CrossRefPubMed
85.
Zurück zum Zitat Mathiowetz V, Matuska KM, Murphy ME. Efficacy of an energy conservation course for persons with multiple sclerosis. Arch Phys Med Rehabil [Internet]. 2001;82(4):449–56.CrossRefPubMed Mathiowetz V, Matuska KM, Murphy ME. Efficacy of an energy conservation course for persons with multiple sclerosis. Arch Phys Med Rehabil [Internet]. 2001;82(4):449–56.CrossRefPubMed
86.
Zurück zum Zitat Mathiowetz VG, Finlayson ML, Matuska KM, Chen HY, Luo P. Randomized controlled trial of an energy conservation course for persons with multiple sclerosis. Mult Scler [Internet]. 2005;11(5):592–601.CrossRefPubMed Mathiowetz VG, Finlayson ML, Matuska KM, Chen HY, Luo P. Randomized controlled trial of an energy conservation course for persons with multiple sclerosis. Mult Scler [Internet]. 2005;11(5):592–601.CrossRefPubMed
87.
Zurück zum Zitat Mulligan H, Wilkinson A, Barclay A, Whiting H, Heynike C, Snowdon J. Evaluation of a fatigue self-management program for people with multiple sclerosis. Int J MS Care [Internet]. 2016;18(3):116–21.CrossRefPubMed Mulligan H, Wilkinson A, Barclay A, Whiting H, Heynike C, Snowdon J. Evaluation of a fatigue self-management program for people with multiple sclerosis. Int J MS Care [Internet]. 2016;18(3):116–21.CrossRefPubMed
88.
Zurück zum Zitat Plow M, Finlayson M, Liu J, Motl RW, Bethoux F, Sattar A. Randomized controlled trial of a telephone-delivered physical activity and fatigue self-management interventions in adults with multiple sclerosis. Arch Phys Med Rehabil [Internet]. 2019;100(11):2006–14.CrossRefPubMed Plow M, Finlayson M, Liu J, Motl RW, Bethoux F, Sattar A. Randomized controlled trial of a telephone-delivered physical activity and fatigue self-management interventions in adults with multiple sclerosis. Arch Phys Med Rehabil [Internet]. 2019;100(11):2006–14.CrossRefPubMed
89.
Zurück zum Zitat Thomas PW, Thomas S, Kersten P, Jones R, Slingsby V, Nock A, et al. One year follow-up of a pragmatic multi-centre randomised controlled trial of a group-based fatigue management programme (FACETS) for people with multiple sclerosis. BMC Neurol [Internet]. 2014;14(1):109.CrossRefPubMed Thomas PW, Thomas S, Kersten P, Jones R, Slingsby V, Nock A, et al. One year follow-up of a pragmatic multi-centre randomised controlled trial of a group-based fatigue management programme (FACETS) for people with multiple sclerosis. BMC Neurol [Internet]. 2014;14(1):109.CrossRefPubMed
90.
Zurück zum Zitat Thomas S, Thomas PW, Kersten P, et al. A pragmatic parallel arm multi-centre randomised controlled trial to assess the effectiveness and costeffectiveness of a group-based fatigue management programme (FACETS) for people with multiple sclerosis. J Neurol Neurosurg Psychiatry [Internet]. 2013;84:1092–9.CrossRefPubMed Thomas S, Thomas PW, Kersten P, et al. A pragmatic parallel arm multi-centre randomised controlled trial to assess the effectiveness and costeffectiveness of a group-based fatigue management programme (FACETS) for people with multiple sclerosis. J Neurol Neurosurg Psychiatry [Internet]. 2013;84:1092–9.CrossRefPubMed
91.
Zurück zum Zitat Miller DM, Moore SM, Fox RJ, Atreja A, Fu AZ, Lee JC, et al. Web-based self-management for patients with multiple sclerosis: a practical, randomized trial. Telemed J E Health [Internet]. 2011;17(1):5–13.CrossRefPubMed Miller DM, Moore SM, Fox RJ, Atreja A, Fu AZ, Lee JC, et al. Web-based self-management for patients with multiple sclerosis: a practical, randomized trial. Telemed J E Health [Internet]. 2011;17(1):5–13.CrossRefPubMed
92.
Zurück zum Zitat Seifi K, Moghaddam HE. The effectiveness of self-care program on the life quality of patients with multiple sclerosis in 2015. J Natl Med Assoc [Internet]. 2018;110(1):65–72.PubMed Seifi K, Moghaddam HE. The effectiveness of self-care program on the life quality of patients with multiple sclerosis in 2015. J Natl Med Assoc [Internet]. 2018;110(1):65–72.PubMed
93.
Zurück zum Zitat Stockl KM, Shin JS, Gong S, Harada ASM, Solow BK, Lew HC. Improving patient self-management of multiple sclerosis through a disease therapy management program. Am J Manag Care [Internet]. 2010;16(2):139–44.PubMed Stockl KM, Shin JS, Gong S, Harada ASM, Solow BK, Lew HC. Improving patient self-management of multiple sclerosis through a disease therapy management program. Am J Manag Care [Internet]. 2010;16(2):139–44.PubMed
94.
Zurück zum Zitat Von Hippel PT. The heterogeneity statistic I2 can be biased in small meta-analyses. BMC Med Res Methodol [Internet]. 2015;15:35.CrossRef Von Hippel PT. The heterogeneity statistic I2 can be biased in small meta-analyses. BMC Med Res Methodol [Internet]. 2015;15:35.CrossRef
95.
Zurück zum Zitat Senchak JJ, Fang CYX, Bauman JR. Interventions to improve quality of life (QOL) and/or mood in patients with head and neck cancer (HNC): a review of the evidence. Cancers Head Neck [Internet]. 2019;4:2.CrossRefPubMed Senchak JJ, Fang CYX, Bauman JR. Interventions to improve quality of life (QOL) and/or mood in patients with head and neck cancer (HNC): a review of the evidence. Cancers Head Neck [Internet]. 2019;4:2.CrossRefPubMed
96.
Zurück zum Zitat Lynch K, Star JR. Teachers' views about multiple strategies in middle and high school mathematics: perceived advantages, disadvantages, and reported instructional practices. Math Think Learn [Internet]. 2013. Lynch K, Star JR. Teachers' views about multiple strategies in middle and high school mathematics: perceived advantages, disadvantages, and reported instructional practices. Math Think Learn [Internet]. 2013.
97.
Zurück zum Zitat Baumstarck K, Chinot O, Tabouret E, et al. Coping strategies and quality of life: a longitudinal study of high-grade glioma patient-caregiver dyads. Health Qual Life Outcomes [Internet]. 2018;16:157.CrossRefPubMed Baumstarck K, Chinot O, Tabouret E, et al. Coping strategies and quality of life: a longitudinal study of high-grade glioma patient-caregiver dyads. Health Qual Life Outcomes [Internet]. 2018;16:157.CrossRefPubMed
98.
Zurück zum Zitat Brunault P, Champagne AL, Huguet G, Suzanne I, Senon JL, Body G, et al. Major depressive disorder, personality disorders, and coping strategies are independent risk factors for lower quality of life in non-metastatic breast cancer patients. Psychooncol [Internet]. 2016;25:513–20.CrossRef Brunault P, Champagne AL, Huguet G, Suzanne I, Senon JL, Body G, et al. Major depressive disorder, personality disorders, and coping strategies are independent risk factors for lower quality of life in non-metastatic breast cancer patients. Psychooncol [Internet]. 2016;25:513–20.CrossRef
99.
Zurück zum Zitat D’Onofrio G, Simeoni M, Rizza P, Caroleo M, Capria M, Mazzitello G, et al. Quality of life, clinical outcome, personality and coping in chronic hemodialysis patients. Ren Fail [Internet]. 2017;39:45–53.CrossRefPubMed D’Onofrio G, Simeoni M, Rizza P, Caroleo M, Capria M, Mazzitello G, et al. Quality of life, clinical outcome, personality and coping in chronic hemodialysis patients. Ren Fail [Internet]. 2017;39:45–53.CrossRefPubMed
100.
Zurück zum Zitat Liddy C, Blazkho V, Mill K. Challenges of self-management when living with multiple chronic conditions: systematic review of the qualitative literature. Can Fam Phys [Internet]. 2014;60(12):1123–33. Liddy C, Blazkho V, Mill K. Challenges of self-management when living with multiple chronic conditions: systematic review of the qualitative literature. Can Fam Phys [Internet]. 2014;60(12):1123–33.
101.
Zurück zum Zitat Hind D, Cotter J, Thake A, Bradburn M, Cooper C, Isaac C, et al. Cognitive behavioural therapy for the treatment of depression in people with multiple sclerosis: a systematic review and meta-analysis. BMC Psychiatry [Internet]. 2014;14(1):5.CrossRefPubMed Hind D, Cotter J, Thake A, Bradburn M, Cooper C, Isaac C, et al. Cognitive behavioural therapy for the treatment of depression in people with multiple sclerosis: a systematic review and meta-analysis. BMC Psychiatry [Internet]. 2014;14(1):5.CrossRefPubMed
102.
Zurück zum Zitat Braley TJ, Chervin RD. Fatigue in multiple sclerosis: mechanisms, evaluation, and treatment. Sleep [Internet]. 2010;33(8):1061–7.CrossRefPubMed Braley TJ, Chervin RD. Fatigue in multiple sclerosis: mechanisms, evaluation, and treatment. Sleep [Internet]. 2010;33(8):1061–7.CrossRefPubMed
103.
Zurück zum Zitat Janardhan V, Bakshi R. Quality of life in patients with multiple sclerosis: the impact of fatigue and depression. J Neurol Sci [Internet]. 2002;205(1):51–8.CrossRefPubMed Janardhan V, Bakshi R. Quality of life in patients with multiple sclerosis: the impact of fatigue and depression. J Neurol Sci [Internet]. 2002;205(1):51–8.CrossRefPubMed
104.
Zurück zum Zitat Kim S, Xu Y, Dore K, Gewurtz R, Lariviere N, Letts L. Fatigue self-management led by occupational therapists and/or physiotherapists for chronic conditions: a systematic review and meta-analysis. Chronic Illness [Internet]. 2021. Kim S, Xu Y, Dore K, Gewurtz R, Lariviere N, Letts L. Fatigue self-management led by occupational therapists and/or physiotherapists for chronic conditions: a systematic review and meta-analysis. Chronic Illness [Internet]. 2021.
105.
Zurück zum Zitat Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta analysis. BMJ [Internet]. 2003;327:557.CrossRefPubMed Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta analysis. BMJ [Internet]. 2003;327:557.CrossRefPubMed
106.
Zurück zum Zitat Parks NE, Jackson-Tarlton CS, Vacchi L, Merdad R, Johnston BC. Dietary interventions for multiple sclerosis-related outcomes. Cochrane Datab Syst Rev [Internet]. 2020;5 Parks NE, Jackson-Tarlton CS, Vacchi L, Merdad R, Johnston BC. Dietary interventions for multiple sclerosis-related outcomes. Cochrane Datab Syst Rev [Internet]. 2020;5
107.
Zurück zum Zitat Motl RW, McAuley E, Snook EM, Gliottoni RC. Physical activity and quality of life in multiple sclerosis: intermediary roles of disability, fatigue, mood, pain, self-efficacy and social support. Psychol Health Med [Internet]. 2009;14(1):111–24.CrossRefPubMed Motl RW, McAuley E, Snook EM, Gliottoni RC. Physical activity and quality of life in multiple sclerosis: intermediary roles of disability, fatigue, mood, pain, self-efficacy and social support. Psychol Health Med [Internet]. 2009;14(1):111–24.CrossRefPubMed
108.
Zurück zum Zitat Salkind, NJ. Ceiling effect SAGE [Internet]. 2010 [Cited 2021 Sep 5]. Salkind, NJ. Ceiling effect SAGE [Internet]. 2010 [Cited 2021 Sep 5].
Metadaten
Titel
Understanding lifestyle self-management regimens that improve the life quality of people living with multiple sclerosis: a systematic review and meta-analysis
verfasst von
Olivia C. Wills
Yasmine C. Probst
Publikationsdatum
01.12.2022
Verlag
BioMed Central
Erschienen in
Health and Quality of Life Outcomes / Ausgabe 1/2022
Elektronische ISSN: 1477-7525
DOI
https://doi.org/10.1186/s12955-022-02046-1

Weitere Artikel der Ausgabe 1/2022

Health and Quality of Life Outcomes 1/2022 Zur Ausgabe